key: cord-0030737-p9nuriip
authors: nan
title: Abstracts zum 128. Kongress der Deutschen Gesellschaft für Innere Medizin e.V.
date: 2022-04-29
journal: Internist (Berl)
DOI: 10.1007/s00108-022-01339-3
sha: dc2c0ca608b53e61637f46344605c47e06052cd0
doc_id: 30737
cord_uid: p9nuriip

nan

dienst, der aufgrund eines Notrufs oder einer ärztlichen Einweisung tätig wird. Er eine wichtige Rolle hinsichtlich der Wahrung der Patientenwünsche ein.

Materialien: In einer anonymen, freiwilligen und einfach verblindeten Studie wurden Hausärzte (HÄ) sowie Notfallsanitäter und Rettungsassistenzen (NuR) im Großraum Frankfurt a. M. über die eigenen Erfahrungen mit der Versorgung präterminal und terminal erkrankter Patienten online befragt. Die Einladung der Teilnehmer erfolgte postalisch.

Ergebnisse: 63 HÄ und 52 NuR nahmen an der Studie teil. 21,0 % der HÄ und 11,1 % der NuR (p=0,29) fühlten sich bei der Einschätzung eines Patienten mit palliativer Therapie am Lebensende sich. Bei der Versorgung dieser Patienten waren sich 33,3 % der HÄ und 8,5 % der NuR sicher (p=0,001). 57,1 % der HÄ und 17,8 % der NuR kennen das Konzept des Advance Care Planning (ACP) (p < 0,001). 77,8 % der HÄ und 91,1 % der NuR denken (p=0,004), dass der Rettungsdienst immer bzw. oft nach Patientenverfügungen (PV) fragt. Nach einer Patientenverfügung fragten selbst immer bzw. oft 81, 9 % der HÄ und 96, 2 % der NuR (p=0, 04) . Die Verständlichkeit der PV bereiteten 24,2 % der HÄ und 51,1 % der NuR Probleme (p=0,003). 90,4 % der NuR wünschten sich unbedingt ein Notfalldokument, das leicht ersichtlich den rechtssicheren Willen des Patienten bezüglich medizinischer Maßnahmen darlegt. 54,8% der HÄ und 76,9 % der NuR empfanden (p=0,02), dass der ärztliche Bereitschaftsdienst (ÄBD) häufiger sterbende Patienten ins Krankenhaus einweist. 50,4 % der HÄ und 66,0% der NuR gaben an (p=0, 16) , dass Notärzte sterbende Patienten oft in ein Krankenhaus transportieren lassen. 84,5 % der Teilnehmer würden einen Patienten in der Sterbephase zuhause belassen, wenn dies der schriftlich dokumentierter Patientenwunsch wäre, und 87,5 % würden dies bei einem mündlich überlieferten Patientenwillens so handhaben.

Zusammenfassung: Die Versorgung eines Menschen an seinem Lebensende ist eine Herausforderung für HÄ und NuR. Beide stehen einer Versorgung im häuslichen Umfeld der Patienten in der präterminalen und terminalen Lebensphase eher positiv gegenüber. Die Wünsche der Patienten genießen eine hohe Priorität, aber sie müssen sicher übermittelt werden. Hierfür sollte die Verständlichkeit der PV für die NuR besser werden. Das Konzept des ACP sollte bei HÄ und besonders bei NuR bekannter werden, um in Notfallsituationen vorher festgelegt Handlungskorridore zu nutzen. Gerade bei ungeplanten Versorgungen palliativer Patienten am Lebensende durch den ÄBD, aber auch die Notärzte scheint die Übermittlung des Patientenwillens gestört zu sein, so dass es zu vermehrten Krankenhausaufenthalten kommt. 

Michael Brinkers¹; Gidelher Pfau¹; Frank Meyer² ¹Otto-von-Guericke-Universität zu Magdeburg mit Universitätsklinikum Magdeburg A.ö.R., Abteilung für Schmerztherapie, Klinik für Anästhesiologie und Intensivtherapie, Magdeburg, Germany; ²Otto-von-Guericke-Universität zu Magdeburg mit Universitätsklinikum Magdeburg A.ö.R., Klinik für Allgemein-, Viszeral-, Gefäß-und Transplantationschirurgie, Magdeburg, Germany Aim: To summarize the results of an interdisciplinary clinical work & research group of a pain outpatient clinic & general/abdominal surgery department at a tertiary institution in a representative overview to reflect on upcoming research topics & current trends in the field.

Methods: Synopsis of written publications & lectures on the topic given by the two disciplines in recent years.

-The creation & implementation of an institutional pain management SOP represents a worthwhile & promising endeavor.

-For the ubiquitously possible application of the SOP, it is provided in the form of a pocket-sized manual for the medical staff.

-For quality assurance, the consults for pain patients are supervised by the senior physicians of the outpatient pain division.

-Abdominal surgery poses an increased risk for the occurrence of back pain in later years.

-Own studies provide also reliable data showing effective pain therapy w/ Novaminsulfon/NSAIDs & Dipidolor up to a postop. duration of 8 d; especially for cancer pats., sustained-release opioids + psychotropic drugs should be considered thereafter.

-Medications are then selected based on the pat.'s classification of pain quality, which is complained about.

-In clinical practice, the level of pain is not a basis for assessing the medication required; pain level of the individual pat. is used solely to assess the course of therapy.

-The consults are not solely for the purpose of administering opioids to every pat. requested; the aim is rather the dissemination of the SOP, its internalization by the ward staff &, based on this, the implementation of a therapy adapted to the individual case -therefore, it seems necessary to increase the No. of consults in the long run to get more & appropriate information.

-The goal is to provide consultation beyond the normal consultative case, not to the individual physician but to the ward team. In this context, the pain service is more involved in the inpatient case &, in return, the team is more actively involved in pain management.

-In the best case management scenario, the on-demand medications to be given in addition to the sustained-release opioids are a matter between the consultation service, the nursing staff & the patient.

-Even the student body can be involved in this setting.

-This flattening of structures also increases the personal responsibility of the nursing staff as well as the trainees.

Our own experience with a postop. algorithm shows that a continuation of the administration or combination of NSAIDs/ Dipidolor not only for 3 (according to the previous recommendation) but for Background: With the 2017 legislation, a different approach to cannabis prescribing became possible. At the same time, however, the question arised as to where the benefits and dangers of cannabis medication exist now, in particular, in that the public is being given the option to legally use cannabis.

-health insurance companies, the medical association, the "Medical Service of the Health Insurance Companies" (German abbreviation, "MdK") on previously approved uses (e.g., in case of tumor cachexia and spasticity in MS).

-Chamber of Pharmacists, professional organization and umbrella group. in particular, on self-purchased cannabis preparations were used.

With regard to possible and identifiable consequences, wich can lead to derive reasonable new regulations, the use of cannabis was compared with that of opioids.

-Physicians using cannabis for "confirmed" indications such as tumor cachexia, nausea, and spastic pain in MS; -Physicians who also "try cannabis!" for up to 50 other indications; -Physicians who use cannabis as a bridging measure because they do not have an idea for a particular pain situation (even though there would be other options).

In contrast, there are three types of cannabis preparation: -As tablet, as flower, as a tetrahydrocannabinol(THC)-free preparation on a green prescription.

A comparison in tabular form shows that a danger of addiction in cannabis medication, which also exists with opioids, originates in the uncritical expansion of indications as well as in the use of flowers against "everything".

Conclusion: Addiction to opioid intake has been already known for a long time. Therefore, countermeasures such as stricter indications and quantity limits in non-cancer patients were taken. Against a possibly threatening wave of addiction to cannabis, a further development as well as careful and approved extension of indications, as well as adequate control over flower users, appear indicated.

Magdalena Braun¹; Heike Reinhardt¹; Amelie Rösner¹; Petra Schilli¹; Julius Wehrle¹; Martin J. Hug²; Monika Engelhardt¹ ¹Uniklinikum Freiburg, Klinik für Innere Medizin I; Comprehensive Cancer Center Feiburg (CCCF), Freiburg, Germany; ²Uniklinikum Freiburg, Apotheke; Comprehensive Cancer Center Freiburg (CCCF), Freiburg, Germany Einleitung: Krebserkrankungen erfordern komplexe Therapieschemata, deren Verordnung und Applikation aufwändig sind. Nicht-durchgängige Prozesse und Medienbrüche zwischen Abteilungen und/oder Berufsgruppen können zu Informationsverlust führen und Fehler begünstigen, mit unmittelbarer Auswirkungen auf die Therapiesicherheit. Innerhalb des CCCF besteht deshalb ein zentrales, interdisziplinäres CTx-Vigilanz-System (CVS) welches durch 4 Elemente Grenzen sehr effektiv überwindet: 1) detaillierte CTx-Protokolle, inkl. Begleitmedikation, 2) SOPs & Behandlungspfade, 3) ein CTx-Management Team (CTx-MT) und 4) eine elektronische Bestelldatenbank (e-DB).

Die in Freiburg verwendete web-basierte e-DB enthält >600 standardisierte und vom CTx-MT regelmäßig aktualisierte Therapieprotokolle (Blaues Buch[1]). Ärztliches Personal generiert elektronische CTx-Bestellungen, welche durch die Apotheke und ein pharmazeutisch besetztes CTx-MT bearbeitet werden. Jeder gefundene Fehler wird unmittelbar durch den Verordner korrigiert und kann so wirkungsvoll beim Patienten (Pat) vermieden werden. Für fehlerfreie Bestellungen wird ein detaillierter Pat-individueller Behandlungsplan via e-DB erstellt und auf Station gesendet. Initial von Hand und später mittels e-DB analysierten wir alle CTx-Bestellungen zwischen 2005 und 2020 hinsichtlich ihrer Fehlerrate: 2005 betrug diese 4,2%. Durch die systematische Einführung der e-DB mit integriertem Standardprotokollsatz im Jahr 2006 halbierte sich diese Rate und bleibt seither konstant bei ~2%. Dank zusätzlicher Dreifach-Kontrolle durch CTx-MT, Apotheke und Station werden darüber hinaus >99,9% aller medizinischen Fehler aufgedeckt und vermieden. [2] [3] [4] [5] Initial wurde dieses CTx-System in der Klinik für Innere Medizin I implementiert, mittlerweile erfolgte der Anschluss aller CTx-applizierenden Fachabteilungen. Durch eine Firmenkooperation wurde das digitale, hauseigene System zudem für externe Praxen und Kliniken im deutschsprachigen Raum zugänglich gemacht. Bei zweifelsfrei | 309 hohem Nutzen auch für externe e-DB Anwender werden dabei aktuelle Grenzen sichtbar: Unterschiedliche Interessen von Kliniken und Software-Firmen sowie Insellösungen bei der Digitalisierung induzieren Verzögerungen sowie Schnittstellen-Herausforderungen und limitieren die tiefe Integration in klinische Prozesse. Im Rahmen eines ZIM/BMBF-Projekts wird aktuell an der optimierten Vernetzung gearbeitet.

Schlussfolgerung: Das interdisziplinäre CVS steigert nachweislich die Qualität der CTx-Verordnungen, erhöht die Therapiesicherheit und führt zu Arbeitserleichterung auf Station. Trotz des großen Verbesserungspotentials durch ein elektronisches Bestellsystem, können 30-40% der Fehler nicht allein elektronisch kontrolliert vermieden werden. [4, 5] Für vollständig sichere CTx-Verordnungen bleibt das CTx-MT somit essentiell. Außerdem sind einheitliche Digitalisierungslösungen unbedingt anzustreben, um die Therapiesicherheit damit weiter zu erhöhen. Einleitung: Die COVID-19 Pandemie stellt unsere Gesellschaft vor ungeahnte Herausforderungen. Dies gilt nicht nur für die medizinischen Versorgung, sondern auch für die medizinische Lehre. In Anlehnung an das "Klinische Forum mit Fallvorstellungen aus dem gesamten Gebiet der Inneren Medizin" des DGIM-Kongress und das gleichnamige Wahlfach der Medizinischen Universität Graz, wurde durch studentische Initiative im WS 2021/2022 im Fachbereich Medizin der Philipps-Universität Marburg erstmals eine web-basierte Fallvorstellung initiiert, über deren erste Ergebnisse im Folgenden berichtet wird.

Methode: Zur Kontaktvermeidung wird die Lehrveranstaltung im zweiwöchigen Rhythmus als Web-basierte, freiwillige Veranstaltung auf der Plattform BigBlueButton angeboten. Die Studierenden (PK und LR) bereiten unterstützt durch erfahrene Kliniker eine Kasuistik vor und präsentieren diese schrittweise. Zusätzliche Interaktion wird neben der Chatfunktion durch das Audience Response System "Poll Everywhere" erreicht. Abschließend folgen einige prägnante "Blick-diagnose-Bilder". Zur Lernerfolgskontrolle findet anfangs jedes Mal eine Überprüfung mit Bezug auf das vorige Seminar statt. Zur Projektverbesserung evaluieren die Studierenden das Seminar kontinuierlich.

Ergebnisse: Die Veranstaltung "Vom Symptom zur Diagnose" wurde von Anfang an sehr gut besucht und hat zwischen 75 und 150 Teilnehmer (Anzahl zugrunde liegender Frageböge n=124). Wie von uns intendiert kommt die Mehrzahl der Studierenden aus den klinischen Semestern (1. klin.: 28,5%; 2. klin.: 27,6%; 3. klin. Studienjahr: 16, 3%; 1%) . 97,6% der Studierenden gaben an, dass ihnen die Veranstaltung Spaß bereite und 96,7% berichten von einem Mehrwert für ihr fachliches Wissen. Zentrale Gründe zur Teilnahme sind das Lernen diagnostischen Vorgehens (96,6%) und das Kennenlernen neuer Krankheitsbilder (97,5%). Weiterhin möchten 96,7% der Studierenden relevante Blickdiagnosen erlernen. Das Tool "Poll Everywhere" wird sehr positiv angenommen und 95,8% der Studierenden sehen hierdurch einen Zuwachs an Interaktionsmöglichkeiten. Durch wiederholte, abgewandelte Prüfungsfragen zeigt sich ein guter Lernerfolg. So erkannten beispielsweise initial 22% der Studierenden eine zirkumskripte Sklerodermie, bei Kontrolle nach zwei Wochen 36%.

Diskussion: Die Corona-Pandemie ist Herausforderung und Chance gleichermaßen, was zur Entwicklung dieses Lehrprojektes führte. Durch die Auswahl spannender Kasuistiken und einer gut strukturierten Präsentation kann digitale Lehre durch den Einsatz moderner Tools attraktiv und lehrreich gestaltet werden. Um nicht immer wieder und überall "das Rad neu erfinden" zu müssen, schlagen wir den Aufbau einer semesterbezogenen, bundesweiten Lehrmediathek vor.

Danksagung: PK & LR wurden mit dem Preis "Lehre@Philipp 2021" der Philipps Universität ausgezeichnet. Neben dem Patientenrechtegesetz von 2009 hat die Bundesregierung mit dem § 132g SGB V im Jahr 2015 ein weiteres Gesetz zur Stärkung der Selbstbestimmung verabschiedet. Damit wurden Beratungen zur Gesundheitlichen Versorgungsplanung Kassenleistung, allerdings zunächst nur für Bewohner*innen stationärer Einrichtungen der Alten-und Behindertenhilfe. Das sich international verbreitende Konzept (im Englischen als "Advance Care Planning" (ACP) bezeichnet) umfasst den durch spezifisch dafür ausgebildete Berater*innen begleiteten Prozess der Auseinandersetzung einer Person mit ihren Wünschen und Zielen für eine künftige medizinisch-pflegerische Versorgung. Die Person wird dabei durch die Berater*innen unterstützt, für künftige Entscheidungen zugrundeliegende Werte und Vorlieben zu erkunden, zu reflektieren und diese mitzuteilen. Die Behandlungswünsche können dann in Form einer Patientenverfügung, eines Not-fallbogens2 oder anderen Dokumenten verschriftlicht werden3-5.

Entscheidend ist aber die konkrete Umsetzung der Behandlungswünsche, die Weichenstellung im Vorfeld einer akuten medizinischen Krise, das vorausschauende Planen einer den Wünschen entsprechenden Behandlung. Dies gelingt nur mit einem guten Netzwerk aus regionalen Akteuren, das u.a. Rettungsdienst, Hausärzte, Pflegedienste und Palliativteams umfasst. Leider kennen bisher nur wenige Ärzte das Konzept und die Umsetzung der Behandlungswünsche scheitert mitunter an mangelnder Information.

Wir begleiten die Entwicklung des Konzeptes ACP und seiner Umsetzung in Deutschland auf verschiedenen praxisrelevanten Ebenen sehr eng: wir beraten selbst, bilden Berater*innen zur Gesundheitlichen Versorgungplanung aus, koordinieren das regionale ACP-Netzwerk "Runder Tisch ACP Thüringen" und arbeiten in ACP-Gremien bundesweit mit. Aus dieser vielfältigen Praxiserfahrung heraus möchten wir dieses ethisch gut fundierte Konzept einer umfassenden Beratung zu Versorgungswünschen gerne den Kolleg*innen auf dem Kongress der DGIM vorstellen. 

We present the first CDSS for alerting Ca disorders in clinical application. Translating fCa measurements to aCa and tCa results was mandatory for finding the first evidence-based cutoffs for severe Ca disorder detection. Through our cutoffs and follow-up time, critical ill patients were specifically detected. Our findings suggest a lack of awareness for inpatients with severe Ca disorders. Employees at the wards were provided with further therapy recommendations. Time savings for physicians and increased patient safety are feasible using AMPEL. 

Schlussfolgerung: Die das viszeral-/onkochirurgische Profil überschreitenden vaskulären Versorgungsansprüche für ein prognostisch besseres onkochirurgisches Langzeit-"Outcome" erfordern eine ausgesprochene klinische und gefäßchirurgisch-rekonstruktive Expertise sowie eine entwickelte interdisziplinäre Zusammenarbeit nicht zuletzt mit interventioneller Radiologie und Intensivtherapie im perioperativen Management.

Rethinking autopsy procedures in the era of pandemics Background: The holistic approach of autopsies allows the detection and characterization of novel diseases. The pandemic of Covid-19, caused by the novel SARS CoV-2 has therefore incited autopy studies worldwide. However, Covid-19 is an infectious disease and precautions are accordingly strict leading to diminished interest of clinicians, as well as relatives regarding consent. Hence, less invasive and less repugnant tools of postmortem tissue aquistion are in demand. To address these needs, several study groups including our multicenter project have examined the use of a minimally invasive autopsy appoaches (MIA) in COVID-19 casualties. It has become clear that ultrasound guided MIA contributes to an increase of postmortal examinations leading to a better understanding of the pathogenesis. Thus, we coined operating procedures for postmortal ultrasound-guided multiorgan biopsies.

Design: In many countries ultrasound exams of COVID-19 patients is the domain of internal medicine specialists, for both diagnostic an interventional procedures. Why not expanding this knowledge to the pathology department and form an interdisciplinary team, fusing the ultrasound skills and knowledge of clinicians with the postmortal experience of pathologists? This is the principle of the ultrasound-based "minimal invasive autopsy" (MIA) procedure.

The interventionalist is providing the best ultrasound-guided biopsy localisation possible and the pathologist guides the biopsy needle through the needle guide clipped on ultrasound transducer, accustically lead by the ultrasound interventionalist controlling the real time picture. This "four-hands"-procedure leads to shorter biopsy times and also to a better quality control of the tissue specimen, as the samples from the 14 Gauge highspeed biopsy needle system are juged immediately macroscopically by the pathologist while the interventionalist can already get ready for the next biopsy location in the postmortem.

We recommend an "interdisciplinary postmortal biopsy team" consisting of an internal medicine-(or in some countries) radiology-based ultrasound interventionalist and a pathologist performing the procedure together.

Igli Kalaja¹; Bettina Kirstein²; Stefan Ulbrich²; Adrian Mahlmann*¹; Jakub Tomala*² ¹Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität, Dresden, Germany; ²Department of Cardiac Electrophysiology, Heart Center, Technische Universität, Dresden, Germany Introduction: The aim of the study is to evaluate the changes in aortic stiffness and cardiac function in young patients who underwent thoracic endovascular aortic repair (TEVAR) after blunt injury of thoracic aorta.

We included 10 patients who underwent TEVAR and 10 healthy controls (matched for sex, age, height, and body surface area). Patients with cardiovascular risk factors, comorbidities with potential impact on arterial stiffness, and prior aortic surgical or endovascular interventions were excluded. Oscillometric measurement of pulse wave velocity (PWV) applying the Gesenius-Keller method (AngE Pro8 Systems from SOT Medical Systems, Maria Rain, Austria) of recording the echocardiogram-triggered pulse waves at different cuff pressures and comprehensive CMR examination including acquistion of isotropic 4D Flow dataset and myocardial mapping were performed in all controls and patients. The mean follow-up period after TEVAR at the time of CMR was 5.4 ± 1.8 years; mean age at the time of TEVAR: 30.3 ± 8.7 years. CMR acquisitions were subsequently analyzed and data regarding global-, segmental aortic PWV, cardiac volumes, systolic-and diastolic function as well as native myocardial T1 and T2 values were collected.

Results: Four TEVAR patients developed arterial hypertension during follow up. Both oscillometric measurement and 4D flow CMR based analysis demonstrated higher global PWV in TEVAR patients. The segmental analysis showed higher PWV in descending-and abdominal aorta (distal to the predominant position of the graft). The indexed diameter of ascending aorta was larger in TEVAR patients with no significant difference in indexed diameter of aortic arch, descendingand abdominal aorta. The analysis of CINE acquisitions demonstrated increased left ventricular myocardial thickness and otherwise no significant difference in cardiac volumes and ejection fraction. Among surrogate parameters indicative of impaired relaxation, tissue-tracking derived 3D global logitudinal diastolic strain rate and velocity (e´) were decreased. Conversely, A-wave velocity derived from 4D flow CMR was increased. Additionally, native myocardial T1 values showed to be significantly increased in TEVAR patients.

Young patients with blunt injury of thoracic aorta appear to be at increased risk of developing vascular dysfuction with secondary diastolic dysfuction due to increased aortic stiffness following TEVAR and further follow up of these patients is warranted. In addition to depiction of vascular anatomy, CMR allows for comprehensive evaluation of vascular stiffness and associated myocardial changes. This capability should be taken into account when considering alternative imaging modalities. 

In eine prospektive klinische Studie wurden Gefäßgesunde verschiedener Altersklassen, Studienteilnehmer mit MM sowie PAVK-Patienten, eingeteilt in Fontaine-Stadien I-IV nach klinischen Kriterien, ohne bzw. mit MM einbezogen. Bei allen Studienteilnehmern erfolgte die CW-dopplersonographische ABI-Kalkulation für A. tibialis posterior (ATP) und anterior (ATA), gefolgt von AT-Bestimmungen im Geschwindigkeits-Zeit-Spektrum der ATP, ATA und A. brachialis (AB) mittels farbkodierter Duplexsonographie. Der AT-Differenzbetrag (AT-DB) zwischen A. brachialis und ATP bzw. ATA wurde als neue Bezugsgröße definiert.

Ergebnisse: Sowohl der AT-DB als auch die AT der ATP, ATA und AB zeigten sich von der Existenz einer MM unbeeinflusst (p>0,05), eine Alters-oder Geschlechtsabhängigkeit der AT bestand nicht. Die Normwerte der AT der Knöchelarterien lagen bei 80,5±10ms (ATA) bzw. 82±11ms (ATP). Die AT-AB für Gesunde betrug 72±8,59ms, die für Probanden mit MM 73±9,0ms. Der AT-DB der ATA betrug 12±9,67ms, der AT-DB der ATP 12±10,16ms. Eine PAVK war ab einer AT von>95 ms zu diagnostizieren. (ATA: Sensitivität: 77%, Spezifität: 90%, PPV: 83%, NPV: 86%) (ATP: Sensitivität: 85%, Spezifität: 87%, PPV: 75%, NPV: 93%) Bestand zusätzlich eine MM, lag eine PAVK ab AT-Werten von >105ms vor (ATA: Sensitivität: 84%, Spezifität: 91%, PPV: 92%, NPV: 81%) (ATP: Sensitivität: 86%, Spezifität: 89%, PPV: 89%, NPV: 86%). Ein AT-DB >20 ms korrelieret mit einer PAVK im Stadium I nach Fontaine (ATA: Sensitivität: 73%, Spezifität 89%, PPV: 79%, NPV: 89%), (ATP: Sensitivität: 82%, Spezifität: 84%, PPV: 66%, NPV: 92%). Dieser AT-DB-Grenzwert galt ebenfalls für PAVK-Patienten mit gleichzeitig vorliegender MM (ATA: Sensitivität: 85%, Spezifität: 68%, PPV: 77%, NPV: 78%), (ATP: Sensitivität: 92%, Spezifität: 80%, PPV: 80%, NPV: 92%).

Zusammenfassung: Mithilfe der AT bzw. des AT-DB gelingt die Quantifizierung des hämodynamischen Schweregrades einer PAVK. Die Unabhängigkeit der AT von einer koinzidenten MM konnte bewiesen werden. Eine multizentrische Studie sollte folgen, um die gefundenen Grenzwerte unter Betrachtung höherer Fallzahlen zu verifizieren. Eine Integration der AT-Messung in die handelsüblichen CW-Doppler-Geräte ist zu empfehlen. However, until now, few data on antibody response with regard to individual autoimmune diseases and immunosuppressive maintenance therapy has been collected. Therefore, we investigated the humoral responses of patients with ANCA-associated vasculitis (AAV) after anti-SARS-CoV-2 vaccination.

In four vasculitis centres, 112 samples were collected from a total of 75 AAV patients three weeks after the first and/or second vaccination, respectively. Kidney function, disease activity, and adverse reactions to vaccination were enquired. Anti-S1 IgG, SARS-CoV-2-specific neutralizing antibodies, and bead-based differentiation of various SARS-CoV-2 target antibodies were determined. In addition, neutralization against B.1.617.2 (delta) was measured using a live virus assay. Responses were compared with age-and vaccine-matched healthy controls.

After the first vaccination, median (IQR) anti-S1 IgG levels were significantly lower in AAV patients with an anti S1-IgG Index of 0.3 (0.1-1.3) compared to 7.1 (1. 5-14.9) in healthy controls (P = 0.024). The same was true for surrogate neutralizing antibodies in AAV patients with an inhibition of 22.5% (11.3-39. 3) compared to 62.2% (29. 2-75.5) in healthy controls (P < 0.001).

After the second vaccination, anti-S1 IgG levels and surrogate neutralizing antibodies increased significantly in both groups (for all P < 0.001). However, median (IQR) anti-S1 IgG levels were lower in AAV patients with 3.4 (0.1-51.1) compared to 144.1 (77.6-278.1) in healthy controls. Surrogate neutralizing antibodies were also significantly lower in AAV patients with an inhibition of 68.5% (30-97) compared to 96.1% (92. 3-97.3) in healthy controls.

Median (IQR) ID50 (equates serum dilution that reduces infection of cells by 50%) was significantly lower in AAV patients compared to the control group with an ID50 of 0 (0-80) compared to 160 (50-320), respectively (P < 0.001). Neutralization against B.1.617.2 (delta) was detectable in 24/24 (100%) healthy controls. In contrast, 29/40 (72%) AAV patients without Rituximab treatment within 12 months prior to their first vaccination and only 1/24 (4%) patients who received Rituximab during this period had detactable neutralizing activity.

Patients with AAV show a reduced humoral vaccine response after standard anti-SARS-CoV-2 vaccination. In particular, the majority of patients who received Rituximab up to 12 months before their first vaccination revealed no detectable neutralizing antibodies against B.1.617. Es wurden die Auswirkungen eines induzierbaren konditionalen Knockouts von Yap und Taz in Endothelzellen in einem murinen Hypertoniemodell untersucht.

Der Allgemeinzustand der Tiere war nach Induktion der arteriellen Hypertonie bei weiblichen und männlichen Tieren gleichermaßen reduziert. Bei den männlichen Tieren war die Letalität von Tieren ohne Knockout geringer als mit Knockout. Bei den weiblichen Tieren war dieser Effekt weniger ausgeprägt. In Abhängigkeit vom Genotyp zeigten sich bei den Tieren Unterschiede an Herz, Nieren, Milz, Leber und Gehirn.

Universitätsklinikum Aachen, AöR, Institut für Experimentelle Innere Medizin und Systembiologie, Aachen, Germany Fibrosis is a key feature of ischemic organ injury characterized by expansion of myofibroblasts and excessive interstitial accumulation of extracellular matrix (ECM). While an adequate myofibroblast response is necessary for tissue integrity and repair, excessive activation leads to scar formation, replacing functional parenchymal tissue, subsequently aggravating organ failure. Although myofibroblasts are considered the main source of ECM in fibrotic disease, newer studies have shown immune cells to be master regulators in myofibroblast activation, orchestrating tissue remodeling with the potential to either ameliorate or aggravate fibrosis. To elucidate macrophage-fibroblast crosstalk after myocardial infarction (MI), we analyzed a publicly available murine MI single cell RNA sequencing (scRNAseq) dataset. Scoring of immune cells based on their expression of ECM regulator genes revealed macrophages to have the highest ECM regulator expression. Subsequent correlation analysis identified Cxcl4 as one of the top genes, correlating with ECM regulator gene expression in immune cells. To test whether Cxcl4 affects development of fibrosis we subjected Cxcl4-/-and WT mice to MI surgery. Loss of Cxcl4 mitigated cardiac | 316 fibrosis, decreased infarction size and preserved left ventricular ejection fraction. To test, whether the observed phenotype is conserved across organs, we performed kidney ischemia reperfusion injury (IRI) in Cxcl4-/-and WT mice. Indeed, Cxcl4-/-mice developed significantly less renal fibrosis. To survey the effect of Cxcl4 on gene expression we sub-clustered macrophages from the MI scRNAseq dataset into Cxcl4-high and Cxcl4-low macrophages. Differential expression analysis revealed an upregulation of genes characteristic for a profibrotic M2-like polarization and a platelet-specific gene signature in Cxcl4high macrophages, pointing towards a possible platelet-macrophage interaction. To validate these findings, we cocultured murine WT and Cxcl4-/-platelets with WT PBMCs. RT-qPCR analysis of FACS-isolated CD11b+ monocytes confirmed that Cxcl4 proficient platelets induce a M2-like monocyte polarization. To examine the influence of platelets on post-ischemic fibrosis, we induced a hematopoietic Cxcl4-KO by bone marrow transplantation of Cxcl4-/-/WT hematopoietic stem cells into lethally irradiated WT mice and subjected them to IRI surgery. As hypothesized hCxcl4-/-mice revealed less M2-like phenotypic macrophage polarization and were protected from fibrosis. To decipher the mechanism of macrophage-myofibroblast crosstalk we performed single nuclear RNAseq from kidneys of Cxcl4-/-/WT mice after IRI. We found a notable expansion of a profibrotic SPP1-positive macrophage cluster with high ECM regulator expression in WT compared to Cxcl4-/-mice after IRI. We hypothesize that transient exposure of monocytes to platelet-derived Cxcl4 drives differentiation to profibrotic SPP1-macrophages, subsequently driving post ischemic organ fibrosis. 

Effects of empagliflozin on uric acid levels and gout: observations from the EMPA-REG OUTCOME trial Background: Higher serum uric acid (UA) levels are associated with gout and other adverse outcomes in patients with type 2 diabetes (T2D). Sodium glucose co-transporter 2 inhibitors lower UA and may reduce gout flares. We studied on-treatment effects of empagliflozin on serum UA levels, prescription of anti-gout/UA-lowering medication, and gout flares in 7020 patients (pooled empagliflozin n=4687; placebo n=2333) with T2D and high CV risk treated in EMPA-REG OUT-COME.

Methods: We assessed effects of empagliflozin versus placebo on UA levels using MMRM analyses; time-to-first occurrence of either an adverse event attributed to gout flare or anti-gout/UA-lowering medication initiation was assessed using Cox proportional hazards models.

Results: From Week 12 onwards, mean UA was reduced with pooled empagliflozin versus placebo; by Week 52, the adjusted mean treatment difference (95% CI) was -0.37 (-0.42, -0.31) mg/dl. Week 52 treatment difference was more pronounced in participants with baseline UA levels ≥6 mg/dl (-0.46 [-0.55, -0 .38] mg/dl). Among 6,607 participants not taking UA-lowering medication at baseline, 5.2% of placebo participants experienced gout flare or initiated anti-gout/ UA-lowering treatment versus 3.6% of pooled empagliflozin participants (incidence rates: 21.6 versus 14.1 events per 1,000 patient-years, respectively; hazard ratio [95% CI]: 0.67 [0.53, 0.85], P=0.001). Risk reduction was similar for both individual empagliflozin doses, and across participants with baseline UA levels below/above 6.0 mg/dl, and across participants with versus without history of gout at baseline (treatment-by-subgroup interaction P=0.53 and P=0.48, respectively).

Empagliflozin versus placebo reduced mean UA, occurrence of gout flares or initiation of UA-lowering medication. Results: Bei unserem ersten Patienten handelt es sich um einen 31-jährigen, normalgewichtigen Mann, der initial im Alter von 2 Jahren mit einem Xanthogranulom am Kinn auffiel. Infolge zeigten sich erhöhte Transaminasen und Cholesterinwerte und bereits eine leichte Hepatomegalie. Es bestanden weder abdominelle Beschwerden noch Gedeihstörungen. Mit 7 Jahren wurde bei ihm die Diagnose einer CESD gestellt. Im Alter von 10 Jahren wurde die Behandlung mit Simvastatin begonnen, wodurch sein Cholesterinspiegel sank. Bei jedoch weiterhin erhöhten Transaminasen wurde im Alter von 26 Jahren eine Enzymersatztherapie mit der inzwischen zugelassenen Sebelipase alfa begonnen, unter welcher die Transaminasen rückläufig waren. Das Statin konnte aufgrund des guten Ansprechens auf die Enzymersatztherapie abgesetzt werden. Die Hepatomegalie war unter der Therapie regredient. Bei unserer zweiten Patientin handelt es sich um eine 53-jährige Frau mit einer Adipositas Grad 2. Ihre leicht erhöhten Transaminasen wurden initial im Kontext der Adipositas als nutritiv bedingte NASH gedeutet und nicht diagnostisch aufgearbeitet. Bei deutlich erhöhtem LDL-Cholesterin (LDL-C) erfolgte die Diagnose nach einer genetischen Untersuchung mit einem, das LIPA-Gen umfassenden, Hypercholesterinämiepanel. Auch der Trockenbluttest bestätigte eine deutlich reduzierte Aktivität der LAL. Eine Affektion S Der Internist · Suppl · | 319 der Gefäße konnte bisher nicht nachgewiesen werden. Sonografisch besteht das Bild einer Steatosis hepatis Grad II. Im Fibroscan zeigte sich ein Fibrosegrad F0-1. Die Therapie mit Sebelipase alfa ist auch bei ihr geplant.

Conclusion: Die zwei Fälle geben einen kurzen Überblick über die CESD und deren Variabilität. Insbesondere der Fall unserer zweiten Patientin soll verdeutlichen, dass es auch wenn eine Transaminasenerhöhung auf den ersten Blick ätiologisch gut erklärbar erscheint, eine weitere Diagnostik bei entsprechender Dyslipidämie sinnvoll sein kann, da sich die Therapieoptionen der LAL-D von denen der Hypercholesterinämie unterscheiden.

Felix Schirmann¹; Tobias Larsen²; Lucy Jones³; Stefan Schmidt⁴ ¹Oviva AG, Science, Potsdam, Germany; ²Oviva AG, Data Science , Potsdam, Germany; ³Oviva AG, Clinical , Potsdam, Germany; ⁴Oviva AG, Potsdam, Germany Introduction: App-based prevention can facilitate lifestyle changes remotely and at a large scale in individuals at risk of excess weight and obesity, reducing the risk for type 2 diabetes and other associated complications. Eating a healthier diet and increasing physical activity are the key lifestyle changes to reduce such risks. We evaluated the efficacy of an app-based prevention programme aiming to facilitate these key health behavior changes in a German cohort, using real world data.

We collected data from 1400 adults, who participated in a remotely-delivered prevention programme offered by a nutritional care provider that was reimbursed by participants' statutory health insurers. The programme fostered health behaviour changes (e.g. through health education and motivational training for healthy habits), and combined counseling by nutritionists and fully-digital interventions, such as educational app content and prompts for self-monitoring. Weight and health behavior data was collected via questionnaires at the beginning ( ≤ 14 days past start) and at the end (60-90 days after start).

Results: 1400 participants (1306 female, 93 male, 1 not specified; Ø 46.1 years (SD 11.7 )) lost 2.2% weight on average (95% CI [2.02, 2.38]; p < 0.05). 15% of patients lost 5% or more weight and 45% lost 2,5% of weight. Comparison of the questionnaires delivered at the start and the end of the programme (days between questionnaires: Ø 56 days (SD 9 days)) revealed increases in healthy food consumption (e.g. reduced intake of fatty foods; p < 0.05), improved self-regulation (e.g. reduced emotional eating; p < 0.05), increased physical activity (e.g. integrating exercise in daily routines; p < 0.05), and self-reported health status (p < 0.05).

The app-based prevention programme proves to be efficacious for health behavior changes, increasing the consumption of healthier diets and physical activity. The observed weight loss is indicative of a trend towards a clinically meaningful weight reduction. Long-term data is needed to evaluate the stability of the observed health behavior change over time. In addition, further research needs to identify which participants profit (the most) from app-based care with the goal to allocate participants to the most appropriate model of care (fully digital, blended-care, or on-site/non-digital). Laborbefunde zeigten schwere mikrozytäre hypochrome Anämie(Hämoglobin 3,1g/dl), niedrige Ferritin-und Vitamin B12-Werte, variable Cholestase(alkalische Phosphatase 167-224U/l, GGT 70-189U/l), negatives H. Pylori Stuhlantigen und normale Tumormarker(CEA, CA 125, . Ultraschall(US) beschrieb verdickte Magenwände(11mm), und eine echoarme recht gut abgegrenzte Raumforderung von 6cm, mit Gefäßsignal (Farb-Doppler-US) im Zwölffingerdarm mit Verdacht auf ein Ampullom, bestätigt durch Endoskopie und CT. Ductus choledochus war auf 11mm erweitert, mit normalen intrahepatischen Gallengängen und ohne Aszites. Die US-Neubewertung vor dem EUS ergab eine große echoarme intragastrische Raumforderung, die durch Endosonographie (EUS) bestätigt wurde: riesiger gestielter hypervaskulärer Polyp, hindeutend auf Malignität. Der Fall wurde als riesiger antraler gestielter polypoider Krebs interpretiert, der einen Zwölffingerdarmtumor(einschließlich Ampullom) nachahmte, kompliziert mit Blutungen und schwerer Anämie, was die Notwendigkeit einer Operation begründete. Beim chirurgischen Eingriff(2/3Gastrektomie mit gastrojejunaler Anastomose) wurde ein 7cm grosser antropylorischer Tumor entdeckt, der intragastrisch schwebte. Die postoperative Entwicklung der Patientin war günstig und sie wurde am 10.Tag entlassen. Die histopathologische Untersuchung nach der Operation ergab IFP, ohne maligne Zellen.

Zusammenfassung: Magenpolypen können als Invaginationstumoren im Duodenum auftreten, werden mittels US diagnostiziert und von EUS und Endoskopie bestätigt. Daher erfordert der mehrschichti-S Der Internist · Suppl · | 320 ge US-Aspekt des Magens oder intragastrische Raumforderungen das Durchführen von EUS mit Biopsien im klinischen Kontext eines anämischen Syndroms, um die zugrunde liegenden Läsionen zu bestätigen. Die Besonderheit des Falles ist die Diskordanz zwischen US-, endoskopischen-, EUS-und CT-Aspekten und die wechselnde Protrusion in das erste und zweite Duodenalsegment mit konsekutiver Cholestase, die ein Ampullom vortäuschen, aber trotz der schweren Anämie und der Größe des Tumors weder Magenausgangssyndrom, kontinuierliche Blutung noch maligne Komponente aufwies. 0, [0] [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] 5, 7] Min.; [8] [9] [10] [11] [12] [13] [14] [15] 2, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] 3, 5] Min.; sTST 18, 7 [4, 1, 33, 2] und 30,6 [16, 1, 45, 2] Min.; IDSIQ Abschnitt für Schläfrigkeit -0, 6 [-2,2, 0,9] und -2,6 [-4,1, -1,0]. TEAE's wurden bei 32,2 %, 35,3 % bzw. 31,1 % der Patienten im Alter von ≥ 65 Jahren in den Gruppen auf 25 mg, 50 mg bzw. Placebo berichtet. Stürze (n = 1, 1, 4 bei 25 mg, 50 mg, Placebo) und Schwindel (n = 4, 1, 1) traten am seltensten in der 50-mg-Gruppe auf. Schläfrigkeit bei 50 mg Daridorexant trat genauso häufig auf wie in der Placebo Gruppe, (n = 6, 1, 1), während Müdigkeit in beiden Daridorexant-Gruppen (n = 4, 3, 1) häufiger auftrat; die Inzidenz war nicht dosisabhängig. AESI von leichter Intensität wurden bei 2 Patienten ≥ 65 Jahre berichtet (eines in jeder Daridorexant-Gruppe). Es gab keine Hinweise auf Entzugserscheinungen nach Absetzen der Behandlung.

Schlussfolgerung: Daridorexant verbesserte bei älteren Patienten sowohl den Schlaf, als auch die Leistungsfähigkeit am Tag. Es wurden keine Sicherheitsbedenken in dieser vulnerablen Bevölkerungsgruppe identifiziert. 

In zwei randomisierten Phase-3-Studien erhielten erwachsene (18-64 Jahre) und ältere (≥ 65 Jahre) Patienten mit Insomnie (gemäß DSM-5-Kriterien) nach Randomisierung (1:1:1) orales Daridorexant 25 mg, 50 mg oder Placebo (PBO) (Studie 1, NCT03545191) oder 10 mg, 25 mg oder PBO (Studie 2, NCT03575104) für 3 Monate. Jede Studie umfasste eine 7-tägige, einfach verblindete PBO-Run-out-Phase nach der doppelblinden Behandlung, zur Beurteilung von Entzugsserscheinungen und Rebound-Insomnie. Entzugserscheinungen wurden anhand der Veränderung des Gesamtscores des Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ) von der letzten Beurteilung der doppelblinden Behandlung bis zum Ende des PBO-Run-out und dem Auftreten relevanter unerwünschter Ereignisse (UE) beurteilt. Rebound-Insomnie wurde objektiv anhand der Veränderung der Wachphasen nach dem Einschlafen (wake-after-sleep-onset, WASO) und der Einschlaflatenz (latency-to-persistent-sleep, LPS) von Baseline (BL) bis zur ersten Nacht des PBO-Runout und anhand der subjektiven Gesamtschlafdauer (subjective total sleep time, sTST) bis zum Ende des Run-out beurteilt (Durchschnitt der 7 Tage). Die Analysen umfassten alle Patienten, die ≥ 1 Dosis der S Der Internist · Suppl ·

PBO-Run-out-Behandlung erhielten (Studie 1: N = 852; Studie 2: N = 851).

Ergebnisse: Es wurde keine Erhöhung des mittleren BSWQ-Scores berichtet (Studie-1: 25 mg, -0,6±2,3; 50 mg, -0,6±2,3; PBO, -0,7±2,3; Studie 2: 10 mg, -0,5±2,6; 25 mg, -0, 4±1, 9; PBO, 4±1, 4) . Am Ende des Run-out hatte keiner der Patienten einen BWSQ-Score > 20. Es wurden keine UE's, die auf Entzugserscheinungen hindeuten, berichtet. Die mittleren WASO-und LPS-Werte (Min.) sanken von BL bis zum PBO-Run-out (WASO Studie 1: 25 mg, 6±55, 5; 50 mg, 5±52, 4; PBO, 4±45, 8; Studie 2: 10 mg, 6±58, 3; 25 mg, 1±57, 9; PBO, Schlussfolgerungen: Bei Pat. mit symptomatischer Retentionspankreatitis und chirurgisch veränderter Anatomie bietet die EU-PD eine sichere Alternative zur erneuten operativen Versorgung.

Es kann eine Verbesserung der Lebensqualität bei akzeptablem interventionellen Risiko erzielt werden. Aufgrund des technisch anspruchsvollen Verfahrens sollte eine EU-PD nur in erfahrenen Zentren durchgeführt werden. 

Reduktion der Häufigkeit und des Schweregrads der typischen Reizdarmsymptome festgestellt, unabhängig vom diagnostizierten Reizdarm-Subtyp. Die Schwere der Abdominalschmerzen sank um 67%, der Diarrhoe um 70%, der Flatulenzen/Meteorismus um 61% und der Obstipation (Subtyp Obstipation) um 79%. Auch der Anteil der Patienten mit dem Gefühl der dringlichen oder unvollständigen Entleerung nahm über 12 Wochen Behandlung hochsignifikant ab (p < 0,001). Insgesamt 94% der Patienten gaben eine gute Verträglichkeit der Therapie mit LP299V an.

Zusammenfassung: Das Mikrobiom als evidenzbasiertes therapeutisches Ziel bei Reizdarmsyndrom hat an Bedeutung gewonnen. Die Ergebnisse dieser Studie bestätigen das Erreichen der primären Therapieziele durch eine Behandlung mit dem Bakterienstamm Lactobacillus plantarum 299v, auch unter Real-Word Bedingungen. Die Daten untermauern die Therapieempfehlung der Leitlinie für eine Behandlung mit LP299V und belegen, dass eine längerfristige Behandlung über 12 Wochen den Therapieerfolg deutlich verstärkt. Methoden: Im Rahmen einer deutschlandweiten Umfrage wurden 13.790 niedergelassene Ärztinnen und Ärzte (Allgemeinmediziner, Internisten) postalisch angeschrieben und zur primärärztlichen Versorgung von Patienten mit symptomatischer unkomplizierter Divertikelkrankheit (SUDD) befragt. Die Erhebung enthielt zudem Fragen zur persönlichen Einschätzung der aktuellen Therapieoptionen sowie den Herausforderungen im Praxisalltag.

Ergebnisse: Insgesamt beteiligten sich bundesweit 526 Ärzte an dieser Umfrage. Generell fühlen sich nur 6% der Ärzte über dieses häufige Krankheitsbild ausreichend informiert. Die SUDD-Symptomatik äußert sich am häufigsten in linksseitigen Abdominalschmerzen (66%), Flatulenz (60%) und Obstipation (46%). Zur Differenzierung zwischen einer SUDD und einem Reizdarmsyndrom werden primär der Nachweis von Divertikeln (25%) und die Lokalisation der Schmerzen (21%) herangezogen. Die Ärzte berichteten dennoch, dass die Abgrenzung eine große Herausforderung darstellt (22%). Ca. 40% der Ärzte gaben an, dass bei einem Drittel ihrer SUDD-Patienten ein unzureichender Therapieeffekt vorliegt. Regelmäßig zur Behandlung der SUDD werden Lebensstil-und Ernährungsempfehlungen (45%) sowie Probiotika (30%) eingesetzt. Nur 13% der Ärzte setzen nie Probiotika bei der Divertikelkrankheit ein. 32% der Ärzte gaben sehr gute bis gute Erfahrungen mit Probiotika bei SUDD an, 25% wechselnde, 22% mäßige und nur 3% schlechte Erfahrungen (keine Erfahrungen bei 19% der Ärzte). Über 60% der Ärzte sind mit der Wirkung von Probiotika zufrieden bis sehr zufrieden. Mesalazin wird sehr selten eingesetzt (8%), wird aber als wirksam empfunden (78%). Ziel: Basierend auf i) gewonnenen klinisch-fallspezifischen Managementerfahrungen und ii) einschlägigen selektiven Referenzen der Literatur, der interessante und bisher eher selten beschriebene Fall eines Patienten mit Sigma-Diverticulitis aufgrund der Komplikation oder der ungewöhnlichen viszeralmedizinischen Nebenwirkung einer laufenden antiinflammatorisch/immunosuppressiv wirkenden Medikation mit einem Januskinase(JAK)-Inhibitor für Rheumatoidarthritis dargestellt werden.

Ergebnisse (Kasuistik): 70-jährige Patientin, die sich wegen seit 24 h progredienten Analschmerzen, beim Sitzen ins Abdomen ziehend, vorstellte.

Anamnese: Rheumatoide Arthritis mit Einstellung auf immunsuppressive Therapie, Osteoporose, Z. n. Extrauteringravidität sowie chronische Gastritis -Vor-Operationen(Op): Cholezystektomie, Varizen-Op, "Total-Op", Bandscheibenvorfall; Medikation: Olumiant® 2 od. 4 mg (Baricitinib = JAK-Inhibitor für die Subtypen 1 und 2; Lilly Deutschland GmbH, Bad Homburg, Deutschland); Calcilac 1x1; Pantozol 40 mg 1x1). 

Schlussfolgerung: Es handelt sich um die erstmalig beschriebene Nebenwirkung unter dem "Paradoxon", dass eine entzündliche Manifestation (Sigma-Diverticulitis) unter antiinflammatorischer Medikation (JAK-Inhibitor) auftritt. Die inflammatorische Reaktion ist möglicherweise als Nebenwirkung der "targeted therapy" oder aber nur spezifisch für JAK-Inhibitoren zu interpretieren. Dabei bleibt unklar, ob das Colon/Colon sigmoideum das einzige Manifestationsorgan darstellt bei der pathophysiologischen Voraussetzung einer Divertikulose als Grunderkrankung. Daneben könnte der eher überwiegende immunsuppressive Effekt der Medikation die antibakteriell-mukosale Immunabwehr im suszeptiblen Colondivertikel als Pathomechanismus alteriert haben. Die begleitende endoluminale Verlaufsbeobachtung der chronischen Gastritis könnte darüber weiteren Aufschluss erbringen. 

immunsuppressiver/antiinflammatorischer Therapie (JAK-Inhibitor) aufgrund einer Colitis ulcerosa, wird ein außergewöhnlich erscheinender Kasus berichtet, trotzdem die Nebenwirkung formal bekannt ist. Es könnte die Manifestation i) einer immunmodulatorisch herabgesetzten mukosalen Abwehr mit erhöhtem Risiko opportunistischer Infektionen als spezifisch viszeraler "side effect" des JAK-Inhibitors und/oder als Folge ii) eines/r induzierten alternativen Entzündungsmechanismus/proinflammatorischen Signaltransduktion bzw. einer intestinalen Abflussstörung im Gebiet der A. colica dextra mit konsekutiver Ansammlung nekrotischer Zellen und Aktivierung von Entzündungsmediatoren sein. -Abdominal CT-scan confirmed ultrasound finding of inflammatory intestinal wall thickening of a diverticulum at the ascending colon with characteristics of a covered perforation.

The patient was admitted to the hospital. Initially, i.v. antibiotic and analgesic therapies were initiated accomplished by i.v. infusion. After temporary "n.p.o.", oral nutrition was carefully initiated, which was well tolerated. In addition, the patient also received nutritional counseling regarding diverticulum.

Course: Under the therapeutic measures, general condition of the patient i and the local pain symptoms mproved rapidly. The infection parameters were regredient; i.v. antibiotic therapy was continued until day 5 to protect. The patient was able to defecate without any problems. For further course, colonoscopy was recommended.

Conclusion: Right-hemicolon diverticulitis is a rare diagnosis based on diverticulosis, which itself shows a high and age-dependent prevalence. In Western industrial countries, approximately 1.5 % of all diverticulitis cases originate at the ascending colon.

This diagnosis needs to be also taken into account in case of right-side lower abdominal pain as one of the possible differential diagnoses (DD) in its broad profile from a surgical perspective. DD includes inner hernia, volvulus (if it occurs also rarely in adults), adhesions (also in subjects with no previous abdominal surgical intervention), appendagitis epiploica, malrotation and others, which can require a demanding diagnostic and therapeuitc management and which needs to be adequately focussed onto and is established for the the specific diagnosis.

Although, there is only a low level of evidence, diverticulitis of the ascending colon is not commonly associated with nausea, vomiting and fever as in appendicitis, which itself occurs more frequently in rather younger patients.

Therapeutic measures are similar to those established for a diverticulitis of the sigmoid colon, which was also successful in the presented case. (n=37) oder Cholangitis (n=32). Im Rahmen der ERCP-Untersuchungen wurden die Stents gesammelt und der Stentinhalt für die Analyse asserviert. Nach der Extraktion erfolgte die miRNA-Quantifizierung mittels qRT-PCR. Für die Analysen wurden folgen miRNA ausgewählt: miR-16 (Gewebsmarker), miR-21 (häufig dereguliert in Tumorerkrankungen) und miR-223 (hohe Konzentration in inflammatorischen Prozesse). Die Normalisierung erfolgte mittels spike-in cel-miR-39.

Ergebnisse: Alle untersuchten miRNA wie miR-16, miR-21 und miR-223 konnten aus den Gallengangsstents erfolgreich nachgewiesen werden. Zur präanalytische Auswertung erfolge eine gepaarte Analyse von Stents des gleichen Patienten zum gleichen Zeitpunkt. Diese zeigten ähnliche Konzentrationsmuster, ebenso zeigten Stents mit unterschiedlicher Liegedauer ähnliche Expressionsmuster. Im Vergleich der malignen mit der non-malignen Kohorte, sowie der BTC-Gruppe und der non-malignen Vergleichsgruppe, konnten keine signifikanten Unterschiede im Expressionsmuster der miR-16 und -21 nachgewiesen werden. Bei der Beurteilung von entzündlichen Veränderungen dagegen konnte bei der Cholangitis-Kohorte im Vergleich zur non-inflammatorischen Gruppe eine erhöhte Konzentration der miR-16, -21 und -223 beobachtet werden (p=0,002, p=0,012, p=0,007).

In dieser Proof-of-Principle-Studie konnten wir zeigen, dass miRNA aus Gallengangsstents erfolgreich gewonnen und reproduzierbar gemessen werden konnten. Die Veränderungen der miRNA-Konzentrationen korrelierten mit einer gesicherten Cholangitis. Es sind weitere Profilingstudien notwendig, um geeignete miRNA als mögliche Biomarker für maligne Erkrankungen zu identifizieren bzw. zu evaluieren. Schlussfolgerung: Beim beschriebenen Fall handelt es sich entweder um eine der 105 bzw. 99 im Beipackzettel gelisteten Nebenwirkungen von Mycophenolat mofetil bzw. Tacrolimus, die als "Kolonentzündung" bzw. "Magen-Darm-Entzündung" aufgeführt sind, oder beschriebene Entzündungsreaktion einer suszeptiblen (gastro-)intestinalen Mukosa durch die transplantationsbedingte immunsuppressive Medikation. 

accuracy of serum interleukin-6 (IL-6) levels as first step in a new diagnostic algorithm for the detection of MHE.

Methods: 197 patients without a history of overt hepatic encephalopathy (OHE) were prospectively enrolled as a development cohort at the Cirrhosis Center Mainz. Another cohort of 52 patients were recruited for validation purposes. The Psychometric Hepatic Encephalopathy Score (PHES) served as the gold standard for MHE diagnosis. IL-6 serum levels were determined at the day of study inclusion immediately after testing with PHES using a commercially available Chemiluminescence immunoassay.

Results: MHE was diagnosed in 50 (25.4%) patients of the development cohort. Median age of the development cohort was 61 years (IQR 54; 67) and the majority of patients were male (n = 110, 55.8%) (median MELD: 10, IQR 7; 13; Child-Pugh A/B/C: 66.5%, 28.4%, 5.1%). Median IL-6 serum level in the total cohort was 8 pg/ml (IQR 5; 18) . Patients with MHE showed significantly higher IL-6 serum levels than patients without MHE (16 vs. 7 pg/ml, p < 0.001). In multivariable analysis, after adjusting for variables such as MELD, albumin, CRP, and history of ascites, elevated IL-6 levels remained independently associated with MHE (OR 1.036, 95%CI 1.009-1.064, p = 0.008). The discriminative ability of IL-6 to detect MHE was fair with an AUROC of 0.751. Using IL-6 as an initial screening test in a stepwise diagnostic algorithm to detect MHE, a cut-off value of IL-6 ≥ 7 pg/ml would have avoided subsequent psychometric testing in 38% of all patients (sensitivity 90%, 95%CI 77%-96%; negative predictive value (NPV) 93%, 95%CI 84%-98%). These results were confirmed in the validation cohort (sensitivity: 94%, NPV: 93%).

Conclusion: Initial determination of IL-6 serum levels in a stepwise diagnostic algorithm could significantly reduce the number of patients who require time-consuming testing with PHES. Introduction: Irritable bowel syndrome (IBS) is a heterogeneous disorder of the gut-brain interaction that impacts up to 10% of adults worldwide. Given its complexities, the treatment of IBS often requires an individualized, multidisciplinary approach, including dietitians and psychologists. Unfortunately, there are significant barriers to patients receiving this care. The aim of this retrospective pilot study was to assess in a real-world setting the ability of an app-based software to assist in the treatment of IBS patients.

Patients with IBS were recruited through on-line advertisement to participate in a 12-week digital treatment program delivered via an app-based medical device ("Cara Care for IBS", HiDoc Technologies GmbH, Berlin) that provided four personalized modules. While every patient received a general health education module, an algorithm considering patient characteristics assigned patients to either one or two of three treatment modules utilizing self-help instructions including nutrition therapy (low-FODMAP diet) and psychotherapy (either cognitive-behavioral therapy or gut-directed hypnosis). IBS symptom severity (IBS-SSS, 0-500) and quality of life (IBS-QOL) were measured at baseline (T0) and every 4 weeks (T1, T2, & T3). Anxiety (GAD-7), depression (PHQ-9), and work productivity and activity impairment (WPAI:IBS) were measured at baseline (T0) and post-treatment (T3). Mixed effect models were used to compare outcomes at T1 -T3 to T0. An interaction analysis was performed to identify the differential patterns of symptom evolution in patients who accessed different treatment modules (e.g., low-FODMAP vs. psychotherapeutic modules).

Results: Of the 80 IBS patients who agreed to participate and initiated the Care Care for IBS app, 54 (67.5%) completed the 12-week program. Compared to baseline, IBS-SSS significantly decreased at T1, T2, and T3 (-89±13, -115±11 pt, -126±11, respectively, all p < 0.001). Likewise, there was significant improvement in IBS-QOL, GAD-7 & PHQ-9. Finally, WPAI:IBS work productivity and activity impairment subscales also significantly improved. Approximately 73% patients at T3 had a clinically relevant improvement in their IBS (defined as >50 point decrease in IBS-SSS). Interaction analysis indicated identical patterns of treatment improvement for each personalized module though the improvement was less for patients who did not enroll in either personalized modules.

The real-world data provide preliminary evidence on the effectiveness of the Cara Care for IBS app software to treat symptoms of IBS and improve quality of life. Punkte bei ED identifiziert werden. In der multivariaten Analyse konnte der MELD Score bei ED (p < 0.001) als negativer sowie eine erfolgte Dilatationstherapie (p=0.001) als günstiger prognostischer Faktor bestätigt werden.

Diskussion: Mit 141 analysierten PatientInnen handelt es sich um das bisher größte klinische Kollektiv von Patienten mit SSC. Als einziger positiver prognostischer Faktor konnte eine endoskopische Dilatationstherapie identifiziert werden. Diese Befunde sollten im therapeutischen Algorithmus berücksichtigt und in prospektiv, multizentrisch bestätigt werden. Introduction: Bacterial infections are associated with a dismal prognosis in patients with liver cirrhosis. Data on their prevalence and the associated pathogen spectra in Germany are scarce. This study aimed to evaluate the impact of bacterial infections on mortality in hospitalized patients with liver cirrhosis and to analyze the prevalence of multidrug-resistant (MDR) bacteria in a German tertiary care center.

Methods: Consecutive, non-electively hospitalized patients with liver cirrhosis were enrolled in this study between March 2019 and June 2021. All patients underwent clinical, laboratory and microbiological testing to detect potential bacterial infections. Patients were followed for 30 days regarding the composite endpoint of death or liver transplantation (mortality).

In total, 239 patients were recruited (median MELD: 18, 62.3% with alcoholic liver disease). Bacterial infection was detected in 81 patients (33.9%) at study inclusion. A total of 70 patients (29.3%) developed a hospital-acquired infection. When comparing community-acquired and hospital-acquired infections, the pathogen pattern shifted from a gram-negative to a more gram-positive spectrum and showed an increase of Staphylococcus spp.. MDR bacteria were detected in 7 infected patients (5.8%). 34 patients reached the composite endpoint during 30-days follow-up. In multivariable logistic regression analysis, the presence of infection during hospitalization remained independently associated with higher mortality (OR 2.522, 95% CI 1.044 -6.091, p = 0.040).

This study demonstrates that bacterial infections are common in hospitalized patients with liver cirrhosis in Germany and are a major determinant of short-term mortality. Our data highlight the importance of regional differences in MDR bacteria and may gui- Introduction: The money counting test is a well-established tool used by pharmacists to quickly evaluate patients' cognition and fine motor skills. Based on a comprehensive geriatric assessment (CGA), the Multidimensional Prognostic Index (MPI) is a much more detailed instrument that enables a very accurate prediction of short-and longterm risk for poor outcomes in advanced aged patients. The aim of the prospective study was to investigate the correlation between the money counting test and the MPI.

Data from 100 patients aged 65 years and older, recruited in a prospective ongoing study were analyzed. All patients underwent a CGA-based MPI calculation upon first visit and were subdivided in low (MPI-1, score 0-0.33), moderate (MPI-2, score 0.34-0.66) and high (MPI-3, score 0.67-1) risk of mortality. In the money counting test, the patients were asked to open a wallet and take out and count the €14.80 it contained. The time required to accomplish this task was measured. The test was aborted if the patients made more than three mistakes or took longer than 300 seconds. If the test was aborted, a time of 300 seconds was recorded.

The median age of the patients was 81 years, 42.0% were female. The median of the money counting test was 84 seconds, the mean time was 126 seconds. In recruitment, MPI-2 was calculated for most patients (61.0%), 9.0% of patients had MPI-1 and 30.0% MPI-3. The mean MPI was 0.56. The partial Spearman correlation coefficient between MPI and time in the money counting test (adjusted by age and sex) was 0.494 (p < 0.001), indicating a significant association.

The results show that the money counting test is associated with the MPI. Since the money counting test takes relatively little time, it is a practical tool to quickly assess patients in the daily clinical routine. Its predictive performance for the prognosis of individual patients remains to be determined.

Krankenhaus am Crivitzer See, Geriatrie, Crivitz, Germany Zielsetzung: Hyperkalzämien sind in der Geriatrie nicht selten; Malnutrition ist häufig, diese wird oft über das Albumin im Serum diagnostiziert. 50 % des Serumkalziums liegen in Proteinbindung, vorrangig an Albumin gebunden, vor. Es existiert eine Rechenformel, mit der ein korrigiertes (und weitgehend "wahres") Serumkalzium errech-net werden kann, basierend auf einer Regressionsanalyse (Payne et al BMJ 1973) . Die Formel ist kaum per Kopfrechnen zu ermitteln, so dass man auf einen Rechner im Internet oder eine App angewiesen ist. Die wenigsten Laborsysteme errechnen das korrigierte Kalzium. Es werden Cutoffs präsentiert, jenseits derer -in Abhängigkeit vom Albumin -bereits eine Hyperkalzämie vorliegt, auch wenn das gemessene Serumkalzium normal ist.

Methoden: Nicht-repräsentativ wurden 10 universitäre und 10 kommerzielle Labore im Internet aufgesucht und die Kalzium-Referenzwerte abgefragt. Die bekannte Rechenformel wurde zu einer Ungleichung umgeformt, so dass für jeden angenommenen Albuminwert zwischen 15 g/l und 40 g/l -in Schritten von 1 g/l -ein gemessener Kalziumwert ermittelt wurde, bei dessen Überschreitung bereits eine Hyperkalzämie vorliegt; die Werte wurden für jedes Labor tabelliert. Für jedes Labor wurde ermittelt, wie viele der 26 Einträge der Tabelle bereits eine Hyperkalzämie anzeigten, obwohl der gemessene Kalziumwert unter dem Mittelwert des Labor-Referenzbereichs lag.

Ergebnisse: Mittelwert und Standardabweichung der Referenzbereiche waren -für die Untergrenze 2,14 mmol/l (0,07 mmol/l) -für die Obergrenze 2,60 mmol/l (0,06 mmol/l) -für die Breite des Referenzbereichs 0,46 mmol/l (0,10 mmol/l) 3 Labore haben Referenzbereiche für Pat. älter als 65 Jahre. 2 Labore errechnen das korrigierte Kalzium automatisch.

Die Tabellen, aus denen der Cutoff entnommen werden kann, bei dessen Überschreitung -in Abhängigkeit vom Albuminspiegel -bereits eine Hyperkalzämie vorliegt, werden vor Ort präsentiert.

Der Median der Anzahl der Tabelleneinträge, die für das Kalzium unter dem Mittelwert des Labors lag, aber gleichwohl schon eine Hyperkalzämie anzeigte, war 16 (von 26 Tabelleneinträgen), Mittelwert und Standardabweichung 15, 9 (1, 93) .

Der Mittelwert des jeweils höchsten Albuminwertes pro Labor, bis zu dem gemessene Kalziumwerte unterhalb des Kalzium-Labormittels bereits eine Hyperkalzämie anzeigten, war 29,9 g/l (Std.abw. 1,93 g/l, Median 30 g/l).

Limitationen sind die Annahme der Gleichverteilung der Hypalbuminämien, die -gleichwohl klinisch relevante -Grenzwertsetzung von 15 g/l "nach unten" und die Auswahl der Labore.

Zusammenfassung: Eine Hyperkalzämie kann in der Geriatrie leicht übersehen werden, wenn das albuminkorrigierte Kalzium nicht errechnet wird. Mit Hilfe der hier errechneten Tabellen lässt sich leicht ablesen, ab welchem gemessenen Kalziumspiegel aufwärts -in Abhängigkeit vom Albumin als unabhängiger Variable -bereits eine Hyperkalzämie vorliegt. Eine Tabelle als Kitteltaschenkarte kann daher hilfreich sein. Background: Prognosis in advanced age is influenced by factors associated with multidimensional frailty, but in urgent settings the comprehensive approach is usually considered unfeasible. Aim of this study was to compare the comprehensive geriatric assessment (CGA)-based multidimensional prognostic index (MPI) with the Sequential Organ Failure Assessment (SOFA-Score) in their predictive value for mortality risk of older patients in intermediate (IMC) or intensive care units (ICU).

Ninety-six IMC or ICU patients older than 65 years underwent SOFA score calculation and assessment of multimorbidity, polypharmacy, cognitive, motoric, daily functions, of social and nutritional aspects; MPI calculation followed, which enabled the classification of patients as at low (MPI-1, score 0-0.33), moderate (MPI-2, score 0.34-0.66), and severe (MPI-3, score 0.67-1) risk of mortality. Patients were contacted 3 months after discharge to collect information on survival and health status.

Results: Almost 40% of the patients belonged to MPI-2 and 54% to MPI-3 group. The MPI confirmed its prediction power for mortality also in older IMC and ICU patients (p=0.042), but it revealed less accurate than that of the SOFA score (p=0.027). The SOFA score correlated moderately but significantly with the MPI (Pearson´s ρ=0.366, p= < 0.001).

In older patients in the IMC / ICU, in which the organ failure determines the critical health condition, the MPI is not superior to the SOFA score for estimating mortality within 3 months from hospitalization. Due to its easier implementation, the SOFA score seems to be the better fit even in advanced age to assess short-term mortality risk in urgent care. However, the age of the patient is not included in the calculation of the SOFA score. Larger studies with longer follow-up periods might show that the MPI may be a good tool for estimating long-term prognosis in older critically ill patients. Background: Prognosis of acute coronary syndrome (ACS) in advanced age is influenced by factors associated with multidimensional frailty, but the comprehensive approach is usually considered unfeasible in non-geriatric settings. Aim of this study was to evaluate the predictive power of the comprehensive geriatric assessment (CGA)-based multidimensional prognostic index (MPI) in older ACS patients.

One hundred eighty-eight patients older than 65 years (76.7±6.6 y, 54F, 134M) admitted to the Heart Centre of the University Hospital of Cologne for instable angina pectoris, non-ST-segment-elevation myocardial infarction or ST-segment-elevation myocardial infarction underwent assessment of multimorbidity, polypharmacy, cognitive, motoric, daily functions, of social and nutritional aspects followed by MPI calculation. Patients were then classified as at low (MPI-1, score 0-0.33), moderate (MPI-2, score 0.34-0.66), and severe (MPI-3, score 0.67-1) risk of mortality. Patients were contacted 6 months after discharge to collect information on survival and health status.

Results: Mean MPI on admission was 0.35 ± 0.15 with 52% of the patients belonging to MPI-1 and 44% to MPI-2. A higher MPI was associated with higher number of daily medication (p < 0.001), higher number of geriatric syndromes (p=0.002), more frequent presence of cardiovascular risk factors including stress (p=0.006) and inactivity/obesity (p=0.025) as well as higher rehospitalization rates over the follow-up period (p=0,024). Patients undergoing percutaneous coronary intervention (64%), coronary artery bypass graft (20%) and medical treatment (16%) were not significantly differently distributed among MPI classes. At the time of abstract submission, analyses are ongoing on the long-term outcomes according to frailty (biological age, MPI score), chronological age and treatment.

In older ACS patients, the MPI confirms as a valid tool for accurate stratification of risk for poor outcomes. Ongoing analyses and further studies will disclose the ability of the MPI of identifying patients particularly benefiting from specific therapeutic options as well as their characteristics. This might improve clinical decision making and, in the context of the upcoming demographic change, help avoiding futility as well as containing rehospitalizations and healthcare resources costs. Objectives: Prognosis of older people is influenced by health-promoting geriatric resources (GR) and life-threatening geriatric syndromes (GS), but little is known about their relationship to organ illness. The aim of the present study was to identify associations of prognostic relevance between patterns of GS, GR and comorbidities.

Methods: Data from 723 older patients undergoing medical treatment for acute nonsurgical illness or relapse of chronic condition were included in the present retrospective analysis. All patients underwent a comprehensive geriatric assessment (CGA)-based multidimensional prognostic index (MPI) calculation and were subdivided in low (MPI-1, score 0-0.33), moderate (MPI-2, score 0.34-0.66) and high (MPI-3, score 0.67-1)-risk of mortality. Organ illnesses according to the Cumulative Illness Rating Scale as MPI item as well as 19 GS and 11 GR were collected in all patients.

One third of the patients (57% M, 78±6 years) belonged to MPI-1 and 52% to MPI-2 risk group. Atrial fibrillation (AF), Chronic Kidney Disease (CKD) and Heart Disease (HD) were the most common conditions, with 2 out of 3 of them in 28% and 1 out of 3 in 25% of the patients. According to the Principal Component Analysis, a higher number of these comorbidities was associated to worse prognosis (median MPI 0.50 in 2-out-of-3 pattern vs 0.38 in 1-out-of-3 pattern, p < 0.001 -adjusted for age and gender). AF and CKD significantly associated with immobility (p < 0.05), polypharmacy (p < 0.001), irritability (p < 0.045) and altered fluid/electrolyte balance (p < 0.001). CKD significantly associated to irritable colon (p=0.002) and impoverishment (p=0.04). HD was significantly associated with polypharmacy (p < 0.001) and irritability (p=0.031). Further analyses are ongoing to disentangle the complex prognostic fingerprint of specific GR-GS-comorbidity patterns.

Conclusions: Common chronic conditions in advanced age appear to be specifically associated to prognostic profiles and patterns of age-related syndromes and resources. The early identification of these profiles might enable the prompt recognition of vulnerable patients thereby improving clinical decision making, outcomes and prognosis as well as avoiding futility and unnecessary healthcare costs. The systematic performance of a structured CGA in nongeriatric settings may be a key element to protect older patients at risk for adverse outcomes. Introduction: Sarcopenia is associated with frailty and reduced quality of life. Especially in patients with liver cirrhosis, sarcopenia has a high impact on mortality. Currently, cumbersome diagnostics are needed to determine low muscle quantity. Sonographic muscle assessment is a simple option, which requires evaluation to be established for diagnostic workup. Therefore, this ongoing study is designated to identify normative age-adapted values of ultrasound muscle indices and compare them with established computed tomography (CT) measurements.

Between March 2020 and July 2021, 355 patients with a median age of 62 were enrolled in the study. Muscle indices, including the psoas muscle area index (PMAI) and the psoas muscle thickness height index (PMTI), were quantified by sonography. Age strata of " < 60, 61-75 and > 75 years" were assessed. In 112 patients, sonographic measurements could be compared with corresponding CT measurements from the transversal section at lumbal level L3/4.

Muscle index measurements identified age-adjusted values for median PMAI (" < 60 years: 487.0mm/m; 61-75 years: 433.7mm/m; > 75 years: 384.1 mm/m") and median PMTI (" < 60 years: 18.8 mm/m, 61-75 years 18.2 mm/m; > 75 years: 17.3 mm/m"). PMTI ("r=0.545, p < 0.01") and PMAI ("r=0.565, p < 0.01") correlated best with CT measurements obtained at the level of L4. Sonographic muscle indices showed a progressive decline throughout aging.

Sonographic muscle quantification is simple, inexpensive and could substitute CT morphometry. Especially, high-risk patients such as those with liver cirrhosis and other wasting entities could be screened.

Methods: Fifty participants aged 72.4±5.8 years (31F) and free from significant pathology underwent computerized cognitive testing (CogState), endothelial function (EndoPAT Index) and heart rate variability (HRV) measurement (Peripheral Arterial Tonometry, PAT), self-assessment of overall health (comprehensive geriatric assessment-based multidimensional prognostic index -selfy-MPI-with subgrouping in low -MPI-1, score 0-0.33-, moderate -MPI-2, score 0.34-0.66-and high -MPI-3, score 0.67-1-risk of poor outcomes) as well as blood withdrawal for metabolomics and HPLC-based analyses of antioxidant micronutrients (six carotenoids, two tocopherols and retinol).

After adjustment for age, gender, MPI as frailty indicator and surrogate marker of biological age and nutritional status according to different models, several significant correlations were found. Plasma concentrations of the carotenoid lutein correlated directly with Endo-PAT Index (p=0.039). CogState subscores of memory function correlated directly with the MPI score (p < 0.005). The metabolomics mortality score was significantly associated to plasma levels of the carotenoid lycopene (p < 0.005), to pulse (p=0.036) and there was a trend to significance for its association to HRV (p=0.07). Glucose levels were significantly associated with both MPI score (p=0.026) and EndoPAT Index (p=0.017). As expected, being carotenoids and tocopherols lipophilic substances, there were strong correlations between metabolomics fatty transporter components and the micronutrients measured.

In this relative small though highly characterized sample, some aspects of the complex interplay between cognitive function, endothelial function, micronutrient and overall health status could be observed. Interestingly, the several associations shown in the present investigation concern frequently recurrent parameters in the field of multifactoriality of aging and of nutritional cognitive neuroscience: The metabolomics mortality score, energy metabolism, heart rhythm and rate, endothelial flexibility, memory performance, as well as lutein and lycopene. Further analyses will help disclosing mechanisms underlying the associations found here. Introduction: While there are clear national resuscitation room admission guidelines for major trauma patients, there are no comparable alarm criteria for critically ill nontrauma (CINT) patients in the emergency department (ED). The aim of this study was to define and validate specific trigger factor cut-offs for identification of CINT patients in need of a structured resuscitation management protocol.

All CINT patients at a German university hospital ED for whom structured resuscitation management would have been deemed desirable were prospectively enrolled over a 6-week period (derivation cohort, n = 108). The performance of different thresholds and/or combinations of trigger factors immediately available during triage were compared with the National Early Warning Score (NEWS) and Quick Sequential Organ Failure Assessment (qSOFA) score. Identified combinations were then tested in a retrospective sample of consecutive nontrauma patients presenting at the ED during a 4-week period (n = 996), and two large external datasets of CINT patients treated in two German university hospital EDs (validation cohorts 1 [n = 357] and 2 [n = 187]).

The any-of-the-following trigger factor iteration with the best performance in the derivation cohort included: systolic blood pressure < 90 mmHg, oxygen saturation < 90%, and Glasgow Coma Scale score < 15 points. This set of triggers identified > 80% of patients in the derivation cohort and performed better than NEWS and qSOFA scores in the internal validation cohort (sensitivity = 98.5%, specificity = 98.6%). When applied to the external validation cohorts, need for advanced resuscitation measures and hospital mortality (6.7 vs. 28.6%, p < 0.0001 and 2.7 vs. 20.0%, p < 0.012) were significantly lower in trigger factor-negative patients.

Our simple, any-of-the-following decision rule can serve as an objective trigger for initiating resuscitation room management of CINT patients in the ED. Introduction: The availability of handheld, noninvasive sublingual video-microscopes allows for visualization of the microcirculation in critically ill patients. Recent studies demonstrate that reduced numbers of blood-perfused microvessels and increased penetration of erythrocytes into the endothelial glycocalyx are essential components of microvascular dysfunction. The aim of this study was to identify novel microvascular variables to determine the level of microvascular dysfunction in sepsis and its relationship with clinical variables.

Methods: This observational, prospective, cross-sectional study included 51 participants, of which 34 critically ill sepsis patients were recruited from intensive care units of a university hospital. Seventeen healthy volunteers served as controls. All participants underwent sublingual videomicroscopy by sidestream darkfield imaging. A new developed version of the Glycocheck™ software was used to quantify S Der Internist · Suppl · | 337 vascular density, perfused boundary region (PBR; an inverse variable of endothelial glycocalyx dimensions), red blood cell (RBC) velocity, RBC content, and blood flow in sublingual microvessels with diameters between 4 and 25 µm.

A detailed analysis of adjacent diameter classes (1 µm each) of vessels between 4 and 25 µm revealed a severe reduction of vascular density in very small capillaries (5 -7 µm) , which correlated with markers of sepsis severity. Analysis of RBC velocity (VRBC) revealed a strong dependency between capillary and feed vessel VRBC in sepsis patients (R^2 = 0.63, p < 0.0001) but not in healthy controls (R^2 = 0.04, p = 0.43), indicating impaired capillary (de-) recruitment in sepsis. This finding enabled the calculation of capillary recruitment and dynamic capillary blood volume (CBVdynamic). Moreover, adjustment of PBR to feed vessel VRBC further improved discrimination between sepsis patients and controls by about 50%. By combining these dynamic microvascular and glycocalyx variables, we developed the microvascular health score (MVHSdynamic™), which decreased from 7.4 (4.6 -8.7) in controls to 1. 8 (1.4 -2.7) in sepsis patients (p < 0.0001) and correlated with sepsis severity.

We introduce new important diameter-specific quantification and differentiated analysis of RBC kinetics, a key to understand microvascular dysfunction in sepsis. MVHSdynamic, which has a broad bandwidth to detect microvascular (dys-) function, might serve as a valuable tool to detect microvascular impairment in critically ill patients.

Literatur: Rovas, A., Sackarnd, J., Rossaint, J. et 

µM für insgesamt 48 h behandelt. Anschließend wurde die Viabiltät mittels Quantifizierung der ATP-Konzentration bestimmt. Um Effekte auf die Metastasierung zu untersuchen wurden ein wound healing/ scratch assay durchgeführt. Dazu wurden die Zellen mit DMF-Konzentrationen von 25 µM -75 µM für insgesamt 48 h behandelt. Da DMF Apoptose induzieren kann wurden die Zellen zusätzlich mit 50 µM zVAD, einen Apoptose-Inhibitor behandelt. Die Migration der Zellen wurde anschließend mikroskopisch verfolgt. Weiterhin wurden die Effekte von DMF auf die Proliferation untersucht. Dazu wurde das Zellwachstum mittels eines kolorimetrischen Assays oder Durchflusszytometrie bestimmt.

Ergebnisse: Die DMF-Applikation resultierte in einer dosisabhängigen Reduktion der ATP Konzentration in allen untersuchten Zelllinien. Die größten Effekte konnten dabei, mit einer Reduktion von 81% der Viabilität, in der Zelllinie HCT116 beobachtet werden. Weiterhin wurde die Migrationsfähigkeit abhängig von der DMF-Konzentration und der analysierten Zelllinie reduziert. Die größten Effekte zeigten sich dabei ebenfalls für die Zelllinie HCT116. Es war ein relativer Lückschluss im wound healing Assay von ca. 4% zu verzeichnen. Weiterhin wurde die Proliferation der verschiedenen Zelllinien untersucht. Es zeigte sich eine dosisabhängige Reduktion der Proliferationsrate in allen untersuchten Zelllinien. Die Zelllinie HCT116 zeigte die größten Effekte auf die Proliferationsinhibition mit einer Reduktion um 89%.

Schlussfolgerung: Die Fähigkeit Metastasen zu bilden erschwert Behandlungen solider Tumore. Wir konnten zeigen, dass DMF sowohl die Migration als auch die Proliferation in verschiedenen malignen Zelllinien inhibieren kann. DMF befindet sich bereits in klinischer Anwendung, anders als gängige Tumortherapeutika weist ein geringes Nebenwirkungsspektrum auf. Deshalb könnte DMF als neue Option gegen die Bildung von Metastasen eingesetzt werden. Background: The intestinal microbiome directly effects outcomes in patients undergoing allogeneic stem cell transplantation (ASCT). Loss of bacterial diversity and domination of single taxa was linked to increased incidence of graft-versus-host-disease (GvHD) and mortality. New developments in microbiome research allow us to look beyond bacteria at the composition of the intestinal fungal and viral communities. We present the first study to integrate these three communities in the ASCT setting together with functional profiling by metabolomics.

We designed a multiomics approach to identify signatures in bacteriome, mycobiome, virome and metabolome in relation to timing and outcomes in ASCT. 353 longitudinal stool samples from 80 ASCT patients were obtained at two centers (Munich and Regensburg). Changes in metabolite composition were evaluated via mass spectrometry, accompanied by bacterial, fungal and viral sequencing. Results were linked among each other and with clinical outcomes. All samples were annotated with treatment data, including antibiotic history.

Results: Longitudinal profiling of ASCT patients revealed a significant loss of bacterial and viral diversity following ASCT. Lower diversity was associated with reduced survival and increased incidence of GvHD. Metabolite analysis provided functional correlates of shifting microbial communities: At baseline, patients had rich metabolite expression profiles, including protective short-chain fatty acids and indoles. Post-transplantation, metabolite levels became progressively more depleted, especially in GvHD patients. We performed network analysis to identify clinical factors that had the highest impact on microbial communities. We discovered that administration of antibiotics had a profound impact of bacteria, fungi and viruses; but most of all had a significant negative effect on metabolites levels. Lastly, we report on a case of successful treatment of severe, steroid refractory GI-GvHD with fecal microbiota transplantation. Response to treatment was characterised by the recipient adopting the FMT donor's rich metabolite expression profile.

To our knowledge, this is the first multicenter study that combines bacteriome, mycobiome, virome and metabolome in a longitudinal fashion in matched patient cohorts. Our results are consistent with previous findings that there are major alterations in gut microbiome and metabolite composition after ASCT. We expand upon those findings by characterizing the time course of phylogenetic alterations and their functional consequences, and linking these changes with clinical outcomes. Patients that retain high-level metabolite expression are protected, and metabolites might serve as biomarkers for lethal GvHD. Our results highlight two strategies for microbiome-based interventions: (1) preventing loss of protective communities and their function by restrictive use of antibiotics and (2) prophylactic administration of metabolites.

fications, in detail inducible activation of the KrasG12D oncogene as well as deletion of the p53 tumor suppressor.

Results: Analysis at 16 weeks post-induction revealed that advanced-stage lung tumors (Adenoma, Adenocarcinoma -Ad/AC) have lower RIPK3 expression than early-stage tumors (bronchial hyperplasia). Lesions with high RIPK3 expression showed smaller tumor sizes and an enrichment of anti-tumoral inducible nitric oxide synthase (iNOS)-positive M2-macrophages as well a reduction in Arginase-1 positive anti-inflammatory M1 macrophages. Observed macrophage polarization suggests that RIPK3 initiates an anti-tumoral immune microenvironment. To evaluate this hypothesis in human settings, we analyzed the TCGA datasets and found that tumors with higher RIPK3 expression showed an increase in immunogenic gene transcription and higher immune cell signals. Leveraging the TGCA, we further identified RIPK3 promoter methylation, which may represent the regulating mechanism of RIPK3 expression.

Conclusion: Taken together our data clearly point to RIPK3 as a tumor suppressor in LUAD. This effect may be driven by the inhibition of necroptotic cell death, which in turn alters immune cell recruitment. Leveraging the crosstalk between inflammatory cell death and immune micro-environment may be a possible immunogenic new therapeutic approach.

Introduction: Variation in risk of dismal outcomes in cancer patients with Covid-19 have often been reported, however, most of these data are not discriminated among different histological subtypes in lymphoma patients. Particularly in the field of Mantle Cell Lymphoma (MCL), data are limited. The European MCL registry is a centralized registry of the EMCL network, collecting real world information about treatments and disease courses. During the Covid-19 pandemic, additional data on MCL patients with Covid-19 infection were collected, aiming to identify risk factors for all-cause mortality from Covid-19.

Methods: This is a retrospective, multicenter, international study of the EMCL network. We collected data from MCL patients in 9 countries (Croatia, France, Italy, Portugal, Spain, Germany, UK, Ireland, and Netherlands) with evidence of a Covid-19 infection between March, 2020 and October, 2021. Information on current lymphoma treatment and remission status as well as Covid-19 disease course and treatment were collected. Severe Covid-19 infection was defined as hospitalization with need of oxygen therapy and/or admission to an intensive care unit (ICU); mild Covid-19 infection was defined as ambulatory care or hospitalization without need for oxygen.

Results: 63 MCL patients with evidence of a Covid-19 infection were identified with a median age of 64 years (range, 44-84) at time of infection, 78% were male and 87% of the patients were on treatment at the time of Covid-19 infection. Regarding the remission status, 70% of the patients were responding (complete remission or partial remission) and 21% of the patients had active disease (stable disease or progressive disease). Of the hospitalized patients (n=46, 73%), 54% had a severe Covid-19 infection with need for oxygen therapy of any kind (including nasal oxygen support, CPAP, Ventilator and ECMO). 34.8% of the patients were admitted to an ICU ward. Overall, 28 patients died after a median follow-up of 26 days (range 1-344). The overall mortality rate was 44.4% and 71.4% of deaths occurred within 30 days of the infection. Especially in hospitalized patients and patients with ICU admission, the mortality was very high (70% and 94%, respectively). Patients receiving Rituximab had significantly poorer OS survival than patients not receiving Rituximab (p=0.04). Of the few vaccinated patients (n=9), 55% (n=5) were hospitalized and all of them were discharged.

Conclusion: Covid-19 infection was associated with very high mortality in MCL patients. Poorest outcomes were observed in patients with progressive disease and requiring hospital admission. Untreated patients had a better chance of survival than those on treatment. Our data highlight the importance of prevention strategies and underline the need for effective vaccination. Additional studies in vaccinated MCL cohorts are needed to understand the Covid-19 disease course better, which is a goal of the EMCL network for 2022.

zen gegenüber DMF frühzeitig zu erkennen, führten wir ein genomweites CRISPR/Cas9 Knock-Out Screening durch.

Über einen lentiviralen Vektor wurde eine Cas9-Sequenz und die Brunello Knockout pooled sgRNA-Library mit 76.000 sgRNAs in T-Zellen der CEM-Zelllinie eingebracht. Die transduzierten Zellen wurden für 12 Tage unter DMF-Behandlung inkubiert und ihre DNA an Tag 0 und Tag 12 isoliert. Bei einer anschließenden PCR, wurden die sgRNA Sequenzen herausamplifiziert und mittels Next-Generation-Sequencing (NGS) sequenziert. Mithilfe des MAGeCK-Vispr Algorithmus, wurden die NGS-Daten bioinformatisch ausgewertet.

Transkriptomanalyse: Zur Generierung DMF-resistenter T-Zellen, wurden Wildtyp-Zellen der T-Zelllinien CEM und HH über mehrere Monate einer langsam steigernden Dosis DMF ausgesetzt. Die mRNA der so erzeugten resistenten Zellen diente als Grundlage für eine vergleichende Transkriptomanalyse.

Ergebnisse: Der MAGeCK-Algorithmus konnte insgesamt 119 Gene identifizieren, deren Knockout zu einer Überrepräsentation in unseren NGS-Daten und damit rückschließend zu einer erhöhten Proliferation unter DMF-Behandlung führten.

Darüber hinaus wurden 102 Gene identifiziert, deren Knockout eine Unterrepräsentation und damit ein besseres Ansprechen auf DMF zur Folge hatten.

Die Transkriptomanalyse der resistenten HH Zelllinie konnte dazu genutzt werden, die Ergebnisse aus dem Screening zu validieren. Insgesamt 23 Gene, die im Screening aufgefallen sind, wurden auch in der Transkriptomanalyse als signifikant verändert identifiziert.

Schlussfolgerung: Es ist uns gelungen, Gene zu identifizieren, die einen signifikanten Einfluss auf die Proliferation von malignen T-Zellen unter DMF-Behandlung haben. Gene, die in allen Analysen als signifikant verändert identifiziert wurden, werden wir nun auch in Patientenmaterial aus der Studie untersuchen. Die Ergebnisse werden es uns ermöglichen Mechanismen zu identifizieren, die zu der Resistenzentwicklung gegenüber DMF beigetragen haben und uns neue Erkenntnisse zum Wirkmechanismus von DMF liefern. Dies ermöglicht die Therapie individuell für die Patienten zu optimieren. Introduction: Transplant-associated microangiopathy (TAM) is a life-threatening endothelial damage syndrome that is increasingly identified as complication after hematopoietic stem cell transplantation (HSCT), comprising severe thrombocytopenia, microangiopathic hemolysis and organ dysfunction (e.g. renal, neurological) in the absence of disseminated intravascular coagulation. Etiological factors include conditioning, immunosuppressive drugs, infections and GvHD. The reported incidence of TAM after allogeneic HSCT varies between 0,5 to 70%. Data for TAM occurrence and outcome in HLA-haploidentical transplantation (haplo-HSCT) are rare. Here, we report on TAM incidence, disease manifestation, treatment and outcome in patients undergoing a first T-cell-replete haplo-HSCT using PTCY as GvHD prophylaxis.

We retrospectively analyzed the treatment course of 172 adult patients undergoing a first T-cell replete haplo-HSCT for malignant and non-malignant hematologic disease at our center from January 2009 to March 2019. All patients were followed for early complications, acute GvHD, infections, survival, as well as for TAM incidence, risk factors, treatment and outcome. The diagnosis of TAM required the fulfillment of the criteria as defined by Ruutu et al., Haematologica 2007. Results: Median age of the entire cohort was 54 years (23-74). 56% of patients was transplanted for myeloid disease. Postgrafting immunosuppression consisted of PTCY, CNI and MMF. Bone marrow was used as graft source in 55% of the patient cohort. Donor sex was male in 52% and female in 48% of the HSCTs. Median follow-up time upon survivors was 4,4 years (4 months -9,5 years). 22/148 patients developed TAM, with a cumulative incidence of 9,6% at day 100. Median platelet count at diagnosis was 20 x 10^9/L (range: 6-146), predominantly de novo or worsening thrombocytopenia. Median LDH level was 411 IU/L (305-1445 IU/L). Serum haptoglobin levels were decreased in 86% of the TAM patients. 14/22 patients had active infection at the time of TAM diagnosis (viral 12/14). All but three patients presented with concurrent active aGvHD requiring systemic steroid treatment (n=18). Renal function abnormalities were diagnosed in 68% of the patients affected by TAM, with 4 patients requiring hemodialysis. Nine patients developed grade III hypertension and three patients showed neurologic dysfunction. Upon diagnosis of TAM, CNI dose was reduced (n=9) or temporarily discontinued (n=7). FFPs were transfused in eleven patients, three patients underwent plasma exchange therapy without any effect. In four patients rituximab was applied.

With a CI of 18% vs 2% (p < 0.001) using a PBSC graft was a risk factor for TAM development when compared to BM. Estimated 3year OS did not differ between the TAM and the non-TAM cohort (48% vs 52%, p=0.75).

Our haplo-cohort showed a TAM incidence of 9,6% at day +100. Disease course was moderate with low TAM-associated mortality. Anamnestisch bestand an Vorerkrankungen ein arterieller Hypertonus sowie ein klarzelliges Nierenzellcarcinom rechts mit einer pulmonalen Metastase Tumorstadium pT2 G2 NO M1 ED 1989. Therapeutisch war 1989 eine Nephrektomie rechts sowie eine Keilresektion der Lungenmetastase erfolgt. Im Anschluss erfolgte eine α-Interferontherapie. In der Nachsorge über 10 Jahre ergab sich kein Hinweis auf ein Rezidiv.

In der klinischen Untersuchung zeigte sich an pathologischen Auffälligkeiten eine diffuse Abwehrspannung sowie fehlende Darmgeräusche. Laborchemisch zeigte sich bis auf eine diskrete Leukozytose keine Auffälligkeiten. Sonographisch konnte bei ausgeprägter Luftüberlagerung kein richtungsweisender Befund erhoben werden.

In einem CT des Abdomens zeigt sich das Bild einer Dünndarminvagination.In einer im Anschluss an das CT durchgeführten Operation imponierte als Ursache für die Dünndarminvagination mit Ileus ein intraluminaler Tumor, welcher sich in der feingeweblichen Untersuchung als Rezidiv des bekannten klarzelligen Nierenzellcarcinoms nach 31 Jahren herausstellte.

In einer erweiterten Staginguntersuchung mittels PET-CT zeigte sich eine Lungenmetastase sowie zwei weitere Metastasen im Bereich der dorsalen Oberschenkelmuskulatur, die operativ R0 reseziert wurden.

Aktuell ist der Patient tumor-und beschwerdefrei und befindet sich in der Nachsorge.

In diesem Fall liegt ein Tumorrezidiv eines klarzelligen Nierenzellkarzinoms nach 31 Jahren und somit weit über dem Zeitraum der Follow-up Nachsorge von 10 Jahren vor. Späte Rezidive sind ein tumorbiologisches Charakteristikum des klarzelligen Nierenzellkarzinoms. Weltweit sind beim klarzelligen Nierenzellkarzinoms in seltenen Fällen, ca 5 % der Patienten, späte Rezidive, definiert als Rezidiv innerhalb von 10 bis 28 Jahren nach Resektion des Primärtumors, beschrieben worden.

Marie Anne-Catherine Neumann¹; Blasius Liss¹; Oliver Schmalz²; Peter Borchmann¹ ¹Uniklinik Köln, Medizinische Klinik I, Köln, Germany; ²Helios Universitätsklinikum Wuppertal, Klinik für Hämatologie, Onkologie und Palliativmedizin, Wuppertal, Germany Introduction: The risk-adapted first-line therapy of classic Hodgkin Lymphoma (cHL) led to high effectiveness and improvement of longterm remission rates. Thereby, the initial treatment consists of multi-agent chemotherapy with or without consolidative radiotherapy. Both genotoxic polychemotherapy and radiotherapy cause acute and long-term toxicities, which may become very severe and raise concern particularly in a young patient cohort. Current clinical research is thus focused on de-toxification. A very promising new treatment principle in this regard is the inhibition of the immune checkpoint receptor programmed cell death protein 1 (PD-1). Recent studies investigated the combination of anti-PD-1 antibodies with chemotherapy as a first-line therapy implying auspicious results (1,2).

Retrospectively, we report on three patients with the initial diagnosis of an advanced stage cHL, whose clinical and laboratory limitation due to the disease made administration of conventional chemotherapy impossible. Patient 1 is a 39-year-old man who presented with persistent fever and an unclear enlargement of abdominal lymph nodes, which was later confirmed as a cHL. His high fever was accompanied by a haemophagocytic lymphohistocytosis, a Coombs-positive anemia and a pronounced bilirubinemia, possibly in the context of a Vanishing Bile Duct syndrome. Patient 2 is a 71-year-old woman, whose initial diagnosis of a cHL was confirmed after presenting with distinct B-symptoms and a cervical lymphadenopathy. Laboratory findings likewise showed a marked bilirubinemia accompanied by a disruption of the hepatic synthesis parameters. Patient 3 is a 68-year-old man, who was admitted with 9 weeks persisting fever and respiratory symptoms, which resulted in the diagnosis of a cHL. He presented with ubiquitous ascites and increased cholestasis parameters, which again was considered as a Vanishing Bile Duct syndrome.

Results: As administration of conventional therapy was impossible and response to pre-phase treatment was unsatisfactory, all three patients received the anti-PD-1 antibody Pembrolizumab or Nivolumab as off-label use due to high therapeutic pressure. Leading to an immense clinical and laboratory improvement, subsequent administration of chemotherapy according to the eBEACOPP or A(B)VD protocol was indicated and possible. Patient 1 achieved a complete remission, patient 2 showed a good partial response and patient 3 a partial response in an interim staging, which without the administration of the PD-1 antibody would probably not have been possible.

Besides being an effective therapy in relapsed and refractory cHL, immunotherapeutic strategies targeting the PD-1/PD-L1 pathway are emerging as a potential therapeutic approach in initially diagnosed patients. As underlined in this case report, it is also a less toxic alternative to common standard polychemotherapy, which provides a therapeutic option for patients unable to receive chemotherapy.

Literatur: 1) P. J. Bröckelmann et al., "Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial," JAMA Oncol, vol. 6, no. 6, pp. 872-880, 2020 , doi: 10.1001 /jamaoncol.2020 -19) . The aim of this study was to explore sonographic muscle indices as predictors of COVID-19 outcome and to test the feasibility of sonographic muscle measurement in an isolation context.

Muscle indices, derived from the psoas muscle or thigh muscles, were quantified by sonography in a cohort of patients without COVID-19 to obtain reference values for low muscle quantity. Gender-specific median of different muscle indices were defined as threshold value for low muscle quantity. The prognostic relevance of low muscle quantity, was prospectively explored in two cohorts of hospitalized COVID-19 patients. Optimal muscle index cutoff values predictive for 30 day mortality during COVID-19 were determined by receiver operating characteristic-area under the curve and Youden index calculation. Muscle quantity and known prognostic factors of COVID-19 were analysed by multivariable log-regression.

Results: Compared with other muscle indices, the psoas muscle area index (PMAI) showed the most favourable characteristics to predict outcome of COVID-19 disease. Sonographic morphometry of patients without COVID-19 (n = 136) revealed a gender-specific median for PMAI (male: 291.1 mm2/m2, female 260.6 mm2/m2) as threshold value of low muscle quantity. Subsequently, COVID-19 patients (Cohort I: n = 58; Cohort II: n = 55) were prospectively assessed by bedside sonography. The studied COVID-19 patients developed a critical course of disease in 22.4% (Cohort I: n = 13/58) and 34.5% (Cohort II: n = 20/55). Mortality rate reached 12.1% (Cohort I: n = 7/58) and 20.0% (Cohort I: n = 11/55) within 30 days of follow up. COVID-19 patients with a PMAI below the gender-specific median showed a higher 30 day mortality in both COVID-19 cohorts (log rank, P < 0.05). The optimal PMAI cutoff value (206 mm2/m2) predicted 30 day mortality of hospitalized COVID-19 patients with a sensitivity of 72% and specificity of 78.5% (receiver operating characteristic-area under the curve: 0.793, 95% confidence interval 0.671-0.914, P = 0.008). Multivariable log-regression analysis of PMAI, age, gender, BMI and comorbidities confirmed S Der Internist · Suppl · | 343 an independent association of low PMAI with 30 day mortality of CO-VID-19 patients (P = 0.018).

Sonographic morphometry provides reliable muscle quantification under hygienic precautions and allows risk stratification of patients with COVID-19. Background: This study assessed non-inferiority of humoral immunogenicity, reactogenicity, and safety of RZV when the 1st dose was co-administered with PCV13 in adults ≥ 50 years of age (YOA) compared to sequential administration.

In this phase 3b, open-label, multi-center study (NCT03439657), adults were randomized 1:1 to receive either the 1st RZV dose co-administered with PCV13 at day (D)1 and the 2nd RZV dose at month (M)2 (Co-Ad group), or PCV13 at D1, the 1st RZV dose at M2 and the 2nd RZV dose at M4 (Control group). Co-primary confirmatory objectives were: (i) vaccine response rate (VRR) to RZV at 1 month post-dose 2 in Co-Ad group; (ii) non-inferiority of humoral responses to RZV (1 month post-RZV dose 2) and PCV13 (1 month post-PCV13) in Co-Ad group compared to Control group. Solicited adverse events (AEs) until D7 post-vaccination and unsolicited AEs until D30 post-vaccination were recorded. Serious AEs (SAEs) and potential immune-mediated diseases (pIMDs) were collected through 12 months post-RZV dose 2. Immunogenicity was performed in the per-protocol set (PPS) and safety analyses in the exposed set.

Of 912 vaccinated adults, 863 were included in PPS Control: 436) . VRR for anti-glycoprotein E antibody concentrations was 99.1% in Co-ad group. The predefined non-inferiority criteria for the humoral immune responses to RZV and PCV13 were met. The overall frequency of solicited local AEs after RZV and PCV13 was comparable between Co-Ad and Control groups. Pain was the most common solicited local AE. The frequency of solicited general AEs was similar for the 1st RZV dose when co-administered with PCV13 or alone (57.4% vs 54.6%). Myalgia and fatigue were the most common solicited general AEs. The frequency (Co-Ad: 21.2%; Control: 23.1%) and nature of unsolicited AEs were balanced between groups. None of the reported SAEs, fatal SAEs, or pIMDs were vaccine-related.

Conclusion: Co-administration of the 1st RZV dose with PCV13 showed non-inferior immune responses to sequential administration. The reactogenicity and safety of RZV in the Co-Ad group were within the range of the established safety profile of RZV. Co-administration of RZV with PCV13 may improve vaccination rates in ≥ 50 YOA population. Background: For over a hundred years viral pandemics recurrently lead to restrictions of public health. Feared characteristics are prolonged recovery and secondary diseases among the surviving. From a socioeconomic perspective medical measures need to be planned efficiently based on significant data. Despite numerous COVID-19 follow-up studies there is still a lack of knowledge in this field.

The prospective controlled cohort Follow-up Study of COVID-19 cases in the district of Konstanz (FSC19-KN) examined 281 adults with PCR-confirmed SARS-CoV2-infection. Initial visits were performed between January and July 2021 at a mean of seven months after infection. In total 238 age-and gender-matched subjects with corresponding cardiovascular risk profile and negative SARS-CoV-2 antibody titers were recruited as controls. Finally, 206 matching pairs could be established. Frequency of inpatient admission during observational period including related diagnosis was defined as primary endpoint. Secondary endpoints included health-related quality of life measured by European Quality of Life-5-Dimensions-5-Level (EQ-5D-5L) and Short Form Health 36 (SF-36), physical performance during six minute walk test (6MWT) as well as functional outcome estimated via Post COVID Functional Scale (PCFS). Data were given as mean ± standard deviation and difference in means (MD) with 95% confidence interval (CI). Strength of association between two events was quantified by odds ratio (OR) with 95% CI.

Results: SARS-CoV-2 positive subjects were mostly symptomatic (95.1%) but hospitalised only to a small extent (2.4%). Frequency of inpatient admission did not differ significantly between both groups (2.4 % positive group vs. 2.9% controls; OR 0.8 CI [0.2; 2.8] ). Relatedness of admission diagnoses to prior infection could not be proven. Results of 6MWT ratio showed no significant difference between both cohorts (0. -4.9; -1.7] ) and mental summary scores (46.3±11.7 vs. 51.9±9.0 controls; ). Reduced functional outcome (PCFS ≥ 2) was detected significantly more often in the SARS-CoV-2 positive cohort (30.6% vs. 14.5% controls; OR 2.6 CI [1.6; 4.2] ). Background: Respiratory syncytial virus (RSV) can cause serious lower respiratory tract disease (LRTD) in older adults. Despite a high burden of disease, there is currently no licensed vaccine for RSV. Here, we report the primary efficacy and immunogenicity results from a Phase 2b proof-of-concept trial of an Ad26.RSV.preF-based vaccine for the prevention of RSV-mediated LRTD in adults aged ≥65 years.

Methods: CYPRESS (NCT03982199) is a randomized, double-blind, placebo-controlled Phase 2b trial. Adults ≥ 65 years of age were randomized 1:1 prior to the RSV season to receive an Ad26.RSV.preF-based vaccine or placebo. Symptoms of acute respiratory infection (ARI) were collected through an RSV-specific patient-reported Respiratory Infection Intensity and Impact Questionnaire (RiiQ) and/or by a clinician assessment until the end of the RSV season. The primary endpoint was the first occurrence of RT-PCR-confirmed RSV-mediated LRTD according to any of 3 case definitions: (1) ≥ 3 symptoms of lower respiratory tract infection (LRTI), (2) ≥ 2 symptoms of LRTI, or (3) ≥ 2 symptoms of LRTI or ≥ 1 symptom of LRTI with ≥ 1 systemic symptom. The secondary endpoint was the first occurrence of any RT-PCR-confirmed RSV-mediated ARI. Immunogenicity assessments were performed in a subset of approximately 200 participants.

Results: A total of 5782 participants (2891 in each study arm) received study treatment (92.5% white, 57.7% female, median age 71 years). Vaccine efficacy was 80% (94.2% CI, 52.2-92.9%), 75% (50.1-88.5%), and 69.8% (43.7-84.7%) for case definition 1, 2, and 3, respectively (all P values < 0.001). All RSV illnesses met case definition 3 and thus, efficacy for any RSV-mediated ARI was 69.8% (95% CI, 42.7-85.1%). In the vaccine arm of the immunogenicity subset, geometric mean fold increase in antibody titers 14 days after vaccination was 13.5 for RSV neutralizing antibodies and 8.6 for RSV prefusion F-specific binding antibodies. Median frequency of RSV-F-specific INFγ T-cells increased from 34 to 444 SFC/106 PBMC 14 days after vaccination in the vaccine arm; no relevant changes were observed in the placebo arm.

In CYPRESS, the Ad26.RSV.preF-based vaccine was highly effective against RSV-mediated LRTD through the first RSV season and elicited robust humoral and cellular immune responses in adults aged ≥ 65 years. Introduction: Against the background of the current COVID-19 infection dynamics with the rapid spread of the Omicron variant, the immunity of health care workers against SARS-CoV-2 continues to be of high importance. The humoral immune response, in particular, is being investigated to provide forecasts regarding immunity and protection against severe disease courses; however, the available data is still insufficient to make any concrete statements based on antibody titres.

The aim of our study was to determine the seroprevalence of SARS-Cov-2-Anti-Spike IgG after SARS-CoV-2 infection or vaccination in healthcare workers.

Methods: 1668 study participants were recruited who met the following inclusion criteria: Age ≥ 18 years, PCR-confirmed SARS-CoV-2 infection and/or vaccination against SARS-CoV-2, working in health care. SARS-CoV-2-Anti-Spike IgG titres were determined by SERION ELISA agile SARS-CoV-2 IgG which shows a high correlation with neutralisation titres with R2 = 0.87 (1). Titres above the threshold of 31.5 BAU/ml indicate at least a moderate neutralisation capacity (2) .

Results: 77.7% (7/9), 95.1% (1428/1501), and 100.0% (60/60) of participants who had received one, two, and three or four doses of vaccination had antibody titres >31.5 BAU/ml. While 98.8% (83/84) of the participants who had recovered from COVID-19 and were vaccinated had neutralising antibody titres >31.5 BAU/ml, only 92.9% (13/14) of the recovered, non-vaccinated participants had titres >31.5 BAU/ml.

Both recovered and vaccinated participants predominantly present a good humoral immune response. After a third vaccination dose, the titres increased significantly. The temporal course of the titres and possible effects on the incidence of SARS-CoV-2 infections in vaccinated and recovered healthcare workers now need to be investigated. Introduction: While SARS-CoV-2 booster vaccinations play an important role in strengthening immunoresponse against SARS-CoV-2, a seasonal influenza vaccination has been an important infection prevention measure for years. The aim of our study was to analyse differences in antibody formation and side effects after SARS-CoV-2 booster vaccinations with and without a co-administered influenza vaccination.

Methods: 751 study participants were recruited, who had received a third SARS-CoV-2-vaccination at least 14 days before participation. SARS-CoV-2-Anti-Spike IgG titres were determined by SERION ELISA agile SARS-CoV-2 IgG and converted to Binding Antibody Units per ml (BAU/ml) according to the First WHO International Standard. SERION ELISA agile SARS-CoV-2 IgG shows a high correlation with titres quantified by plaque reduction neutralisation test (1, 2). Side effects were recorded by an online questionnaire.

Median SARS-CoV-2-Anti-Spike IgG was higher in persons without coadministered influenza vaccination (1803 BAU/ml, IQR: 1136 -2777 BAU/ml) compared to persons with a coadministered influenza vaccination (1560 BAU/ml, IQR: 1085 -2484 BAU/ml), but this difference was not statistically significant (p = 0.058).

No significant differences in reported side effects and incapacity to work (mean duration: 0.42 days vs. 0.52 days, p =0.23) could be observed between persons with and without coadministered influenza vaccine.

A third SARS-CoV-2-vaccination dose induced high antibody titres with and without coadministered influenza vaccination. Coadministration of an influenza vaccine does not lead to increased side effects. As influenza vaccination is an important infection prevention measure, coadministration may increase vaccine uptake. The observed insignificantly lower antibody titres have to be analysed in a bigger cohort. Introduction: The functional assessment of the right ventricle (RV) is a demanding task as evolution has disposed it to be an anatomical backpack of the left ventricle (LV). However, the RV is confronted with the tremendous duty to propel an equal amount of blood just through a smaller circuit. Thus, the pulmonary artery pulsatility index (PAPi) integrating data on RV function and hemodynamics is a useful tool in terminal right heart failure. Nevertheless, its role after heart transplantation is not assessed.

We performed a retrospective analysis of data derived from patients' charts. Additionally, PAPi was calculated using the equation: PAPi = (PAPs -PAPd) / RAP, where PAPs and PAPd are pulmonary artery systolic and diastolic pressures, respectively. RAP refers to right atrial pressure. These values were conducted from the most recent invasive hemodynamic assessment (IHA).

We identified 160 patients with available hemodynamic data post orthotopic HTx. The mean follow-up was 15.1 ± 6.7 years and the last IHA was performed 8.2 ± 6.3 years following HTx. The calculated PAPi values were 4.0 ± 2.7 and did not correlated with the patients` cardiac output (p = 0.76) or cardiac index (p = 0.86). There was a negative correlation between estimated PAPi measures and serum NTproBNP levels (p = 0.04), diuretic treatment (p = 0.02), liver function parameters as gamma-glutamyl transferase (p = 0.04) as well as patients` functional status expressed as NYHA class (p = 0.05) at last follow-up. We observed no prognostic relevance of PAPi in a multivariate logistic regression analysis after adjustment for the above-mentioned determinants (HR 1.05, 95% CI 0.98 -1.12, p = 0.16). However, patients with PAPi in the lower quartile (< 2.3) had a more impaired right ventricular function at last follow-up, expressed as tricuspid annular plane systolic excursion (15.0 ± 3.6 vs. 16.5 ± 4.4 mm, p = 0.049) . Treatment with calcium channel blockers had no influence on the estimated values (p = 0.55).

The estimation of PAPi is based on a simple equation and may help identify failures in the components of the smaller circulation affecting the patients' clinical status. Reduced PAPi is associated with an impaired RV function in the time course after HTx, but we observed no prognostic relevance.

Klinik Schönsicht Berchtesgaden, Rehabilitation für Kinder und Jugendliche, AHB, Kind-Mutter/Vater-Rehabilitation, Berchtesgaden, Germany

Have adolescents and adults < age 21 who develop myocarditis after mRNA COVID-19 vaccination frequently abnormal findings on cMRI and a mild clinical course with rapid resolution of symptoms?

Methods: Literature research.

Results: Using data from 26 pediatric medical centers across the US and Canada, the researchers reviewed the medical records of 139 patients < age 21 with suspected myocarditis within 1 month of receiving a COVID-19 vaccination.

They made the following key observations:

Most patients were male (90.6%), White (66.2%) and with a median age of 15.8 years.

Suspected myocarditis occurred in 136 patients (97.8%) following mRNA vaccine, with 131 (94.2%) following the Pfizer-BioNTech vaccine; 128 cases (91.4%) occurred after the second dose.

Symptoms started a median of 2 days (range 0 to 22 days) following vaccination administration.

Chest pain was the most common symptom (99.3%), with fever present in 30.9% of patients and shortness of breath in 27.3%.

Patients were treated with NSAIDs (81.3%), IVIG (21.6%), glucocorticoids (21.6%), colchicine (7.9%) or no anti-inflammatory therapies (8.6%). 26 patients (18.7%) were admitted to the intensive care unit; 2 received inotropic/vasoactive support; none required extracorporeal membrane oxygenation or died.

Median time spent in the hospital was 2 days.

A total of 111 patients had elevated troponin I (8.12 ng/mL) and 28 had elevated troponin T (0.61 ng/mL).

More than two thirds (69.8%) had abnormal electrocardiograms and/ or arrhythmias (7 with nonsustained ventricular tachycardia).

26 patients (18.7%) had LVEF < 55% on echocardiogram; LVEF had returned to normal in the 25 who returned for follow-up. 75 of 97 patients (77.3%) who underwent cMRI at a median 5 days from symptom onset had abnormal findings; 74 (76.3%) had late gadolinium enhancement, 54 (55.7%) had myocardial edema, and 49 (50.5%) met Lake Louise criteria for myocarditis.

Conclusion: Data suggest that most cases of suspected COVID-19 vaccine-related myocarditis in people < age 21 are mild and resolve quickly.

We pediatricians and cardiologists were very happy to see that type of recovery. However, we are awaiting further studies to better understand the long-term outcomes of patients who have had COVID-19 vaccination-related myocarditis. We also need to study the risk factors and mechanisms for this rare complication.

This study supports what we pediatric cardiologists ‚ve been seeing. People identified and treated early and appropriately for the rare complication of COVID-19 vaccine-related myocarditis typically experienced only mild cases and short recovery times.

Findings support the AHA's position: COVID-19 vaccines are "safe, highly effective, and fundamental to saving lives, protecting our families and communities against COVID-19 and ending the pandemic."

Overwhelmingly, data continue to indicate the benefits of COVID-19 vaccine far outweigh any very rare risks of adverse events from the vaccine, including myocarditis.

University Hospital Würzburg, Department of Internal Medicine I, Würzburg, Germany

Aims: In EMPEROR-Preserved, empagliflozin versus placebo reduced risk of cardiovascular death/hospitalization for heart failure (HHF) by 21%, reduced total HHF by 27%, and slowed eGFR decline (all p < 0.001) in heart failure with preserved ejection fraction, with/without diabetes. We explored empagliflozin treatment effects on outcomes by baseline chronic kidney disease (CKD) status.

Methods: Among 5988 patients, 53% had prevalent CKD (eGFR < 60ml/min/1.73m2 or urine albumin-to-creatinine ratio > 300mg/g). Median follow-up was 26 months. Models used were Cox proportional hazards for cardiovascular death/HHF, joint frailty for total HHF, and random coefficient for eGFR slope.

Results: Patients with versus without baseline CKD were older, had higher NT-proBNP and baseline diuretic use, and had similar rates of baseline diabetes. Patients with versus without prevalent CKD had a higher rate of cardiovascular/kidney events. Effects with empagliflozin versus placebo were consistent regardless of CKD status: CV death/HHF, HR (95% CI) 0.80 (0.69-0.94) with CKD versus 0.75 (0.60-0.95) without, interaction p=0.67; total HHF, 0.68 (0.54-0.86) versus 0.89 (0.66-1.21), respectively, interaction p=0.17; and the difference in eGFR decline was 1.43 (1.01-1.85) with CKD versus 1.31 (0.88-1.74) ml/min/1.73 m2/year without, respectively, interaction p=0.70. Outcomes were consistent even with severe impairment (eGFR 20-30 ml/min/1.73 m2). Empagliflozin was well tolerated regardless of baseline kidney function. Acute kidney injury was less frequent with empagliflozin versus placebo regardless of CKD status.

In EMPEROR-Preserved, empagliflozin reduced serious heart failure events and slowed eGFR decline, regardless of CKD status and across a broad spectrum of baseline kidney function. Background: The therapy of colorectal carcinoma in Stadium III is a combination of Fluoropyrimidine with Oxaliplatin. A preferred therapy is the oral one with Capecitabine due to less side effects and better remission rates. Common side effects are nausea, diarrhea, hand-foot-syndrome. Less common, however life-threatening is the known cardiotoxicity. Most of the cases are coronary artery spasms, acute coronary syndromes, atrial fibrillation, heart failure (Kwakman et al., Frickhofen et al.) . Less known is ventricular fibrillation. So far reported is a single case study (Watford Hospital in Watford, UK) of a 28-year-old patient undergoing therapy with capecitabine in the 5th cycle suffering of a syncope due to ventricular fibrillation. After successful resucitstion and despite ST-elevation no coronary artery disease was documented within the coronarangiography. Therefore, ventricular fibrillation was classified as cardiotoxic side effect of Capecitabine.

A second retrospective publication retrospection by Dyhl-Polk et al. found 6 cases of ventricular fibrillation under treatment of Capecitabine of which one survived and received an ICD.

Methods: Single-case-study of a 48-year-old male patient with cardiac arrest due to ventricular fibrillation undergoing capecitabine therapy due to colorectal carcinoma.

The 48-year-old male patient had prehospital emergency resuscitated due to cardiac arrest and subsequent collision with a car. After two electrical defibrillations due to ventricular tachycardia ROSC was achieved (about 5 minutes resusitation). CT scan showed no relevant trauma or life threatening disease. So did the coronarangiography. ECG with no signs of prolonged QT period. The troponin I and the electrolytes were in standard range. Echocardiography showed a regular left ventricular ejection fraction. Family history was without cardiovascular disease or sudden cardiac death. The patient didn't have any cardiovascular risk factors. However, due to colorectal carcinoma he had capecitabine treatment. It was the 3rd of 8 cycles in an adjuvant scheme with curative intention.

During the ICU stay there were no further arrhythmias. The therapy with capecitabine was resumed. The patient received an ICD. One month later the patient presented with a syncope without trauma. The ICD check revealed two ventricular arrhythmias which got successfully terminated by the ICD.

Here we present a case report of a rare but life-threatening side effect of a capecitabine therapy. A multidisciplinary team should be involved when cardiotoxic medication like capecitabine is being used. Introduction: Peripartum cardiomyopathy (PPCM) remains a major contributor to maternal morbidity and mortality worldwide. The disease is associated with various complications mainly occurring early during its course. Reported adverse outcomes include decompensated heart failure, thromboembolic complications, arrhythmias and death. We aimed to systematically summarize the complications and outcome of women with PPCM across different geographical regions and to identify possible predictors of adverse outcomes.

Methods: For this systematic review and meta-analysis, we performed a comprehensive search of all articles published between January 2000 and June 2021 on PubMed/MEDLINE, Web of Science, Scopus and EBSCO Host, including Academic Search Premier, Africa-Wide Information, CINAHL. All cohort, case-control and cross-sectional studies, as well as control arms of randomized controlled trials (RCTs) reporting on the in-hospital complications and 6-and/or 12-month outcomes of PPCM were considered eligible.

Results: Our search strategy identified 1737 citations, of which 47 studies (4875 participants) were included. Hemodynamic and echocardiographic parameters were similar across all continents. In-hospital mortality was reported as 1.9% [95% CI 0.5-4.0] across all regions. About 10% of patients required invasive ventilation, whereas 21.5% and 3.1% received inotropic and mechanical support, respectively. LV thrombus complicated 9.0% [95% ] of patients and all-cause embolic events (i.e., stroke, arterial embolism, deep vein thrombosis, pulmonary embolus) occurred in 6.1% [95% ]. All-cause mortality was 8.0% [95% studies, I2=93.3%, p < 0.001). All-cause mortality was highest in Africa and Asia/Pacific. Europe and North America reported the highest prevalence of LV recovery. Frequent prescription of beta-blocker, ACE-I/ ARB and bromocriptine/cabergoline treatment were associated with significantly lower all-cause mortality and better LV recovery.

We identified significant regional differences in the prevalence of in-hospital complications, rates of LV recovery and all-cause mortality. Frequent prescription of guideline-directed heart failure therapy and bromocriptine/cabergoline was associated with better LV recovery and lower all-cause mortality. The observed discrepancies in outcome may be linked to differences in access to health care and socioeconomic circumstances.

Universitätsklinikum Münster, Klinik für Kardiologie I: Koronare Herzkrankheit, Herzinsuffizienz und Angiologie, Münster, Germany Background: Emerging data in recent years regarding the role of remnant cholesterol (RC) in coronary artery disease have enhanced our understanding of its pathophysiology, thus becoming a signpost in the therapeutic revolution [1]. Nevertheless, data concerning the population of heart transplant (HTx) recipients are still sparse. Therefore, our study aimed to assess the RC levels and their association with cardiac allograft vasculopathy (CAV) despite secondary prevention in a relatively large cohort of adult HTx patients.

We performed a retrospective analysis of patient data collected at the most recent follow-up, and further assessed the lipid profile and medication at the admission at which CAV was diagnosed. RC levels were calculated using the equation: RC = total cholesterollow-density lipoprotein (LDL) -high-density lipoprotein (HDL).

The overall study population consisted of 184 HTx recipients with a mean follow-up of 15.0 ± 6.8 years. The mean RC levels at the most recent presentation were 27.1 ± 14.7 mg/dL. We stratified the patients into two groups according to these measures -group 1 with RC < 27 mg/dL (n = 100, 54.3 %) and group 2 with RC ≥ 27.0 mg/dL (n = 84, 45.7 %). The later had more often CAV (p = 0.001). We observed no difference in the frequency (p = 0.553) or intensity of statin treatment expressed as pravastatin equivalent dose (PED), (p = 0.371) between groups. An additional assessment of the RC levels in patients with CAV (n = 79, 42.9 %) at the admission at which CAV was diagnosed, revealed that more than half of the cohort (n = 47, 59.5 %) had RC ≥ 27 mg/ dL. Furthermore, 62 of the patients with CAV (78.5 %) were on statin treatment at this time point, with a mean daily PED 41.9 ± 35.4 mg, whereas at the most recent presentation 64 subjects (81.0 %) were on statins with a PED 62.0 ± 57.1 mg/day. The intensified statin treatment at follow-up resulted in more patients reaching the LDL goals recommended for the cardiac transplant recipients (LDL < 100 mg/dL in n = 22, 27.8 % at diagnosis of CAV vs. n = 42, 53.2 % at last follow-up) [2] . No differences in the frequency of RC levels exceeding 27 mg/dl were observed (n = 48, 60.8 % at diagnosis of CAV vs. n = 47, 59.5 % at the most recent presentation). After adjustment for HDL values, LDL levels and statin treatment, RC ≥ 27 mg/dL emerged as a significant factor associated with CAV despite secondary prevention (OR 2.9, 95 % CI 1. 6 -5.3 , p = 0.001).

Conclusions: Patients with CAV have elevated RC levels. Intensified statin treatment helps towards reaching the LDL goals, but we observed no relevant influence on the RC values, thus indicating that future therapeutic strategies should also address the triglyceride-rich lipoproteins in order to achieve adequate disease modification. Charité -Universitätsmedizin Berlin, Stoffwechselzentrum -Lipidambulanz, Berlin, Germany Einleitung: Statinintoleranz stellt auch in Zeiten der PCSK9-Inhibitoren ein Problem in der Patientenversorgung dar, weil ohne die Therapie mit Statinen die vorgegebenen Zielwerte oft nicht erreicht werden. In Deutschland bietet Bempedoinsäure, ein Inhibitor der Adenosintriphosphat-Citrat-Lyase, seit 2020 eine zusätzliche Behandlungsoption für die Senkung des Low Density Lipoprotein (LDL). Das Ziel dieser Analyse ist es, neue Daten zu den bei uns aufgetretenen Nebenwirkungen und der Effektivität von Bempedoinsäure in einer Real-World Kohorte darzustellen.

Methoden: Zur Datengewinnung erfolgte eine retrospektive Analyse der in unserer Lipidambulanz mit Bempedoinsäure behandelten Patienten.

Ergebnisse: 79,7% der von uns mit Bempedoinsäure behandelten Patienten (n=271) litten an einer Statinintoleranz. Das Durchschnittsalter betrug 64 Jahre. 64,8% unserer Patienten waren weiblich. Bisher beendeten 41% die Therapie aufgrund von Nebenwirkungen, unzureichender LDL Senkung oder wenige sogar aufgrund der zusätzlichen Kosten für die geringe Packungsgröße. Hauptsächlich waren Nebenwirkungen wie Myalgien, Arthalgien und gastrointestinale Beschwerden ursächlich für Therapieabbrüche. Patienten die eine Monotherapie mit einem PCSK9-Inhibitoren hatten, profitierten am meisten von der zusätzlichen Gabe von Bempedoinsäure. Bei dieser kleinen Untergruppe (n=13) konnte eine zusätzliche LDL-Reduktion von im Durchschnitt 46,5% erreicht werden.

Methods German claims from AOK PLUS covering the period 04/2014-03/2019 were used in a longitudinal analysis including continuously insured persons aged at least 40 years who were newly diagnosed with COPD (ICD-10 code: J44.-) either by a pulmonologist in an outpatient setting or during an inpatient hospital stay. Patients were excluded if they received medication for COPD during a 12-month pre-index period or were diagnosed with asthma (ICD-10 code: J43.-) in the follow-up period.

Patients' characteristics were based on the pre-index period and compared between the groups using the unpaired t-test for continuous variables and the Chi-Square test for categorical variables. Forced expiratory volume in one second (FEV1) was obtained from ICD-10 subcodes at the index date. Outpatient drug prescriptions were collected during follow-up. Time to treatment initiation and to first severe exacerbation (defined as hospitalization with ICD-10 code J44.1) were analysed using Kaplan-Meier estimation.

Results: Most of the 17,464 incident COPD patients were diagnosed during an inpatient stay (13,660 patients; 78.2%) . Of these, in 17.7% COPD was documented as the main diagnosis for hospitalization. Inpatients diagnosed were significantly older (mean age: 73.2 vs. 65.4 years; p-value < 0.001), had more comorbidities (mean Charlson Comorbidity Index: 5.8 vs. 3.4; p < 0.001) and had a higher percentage of diagnoses without coding of FEV1 than patients with an incident outpatient diagnosis (63.1% vs. 37.2%; p < 0.001). Among patients with specified FEV1 coding, lower values were more frequently observed in the inpatient setting (FEV1 < 50% in 39.0% vs. 29.1%).

Median follow-up period was 660 days for patients with an inpatient diagnosis and 929 days for patients with an outpatient diagnosis. The proportion of patients who did not receive any maintenance therapy in the first year of follow-up was 54.7% for patients with inpatient diagnosis versus 19.7% for patients with outpatient diagnosis (p < 0.001). The time to treatment initiation was shorter in patients diagnosed in an outpatient setting (median: 3 vs. 404 days; p < 0.001). Among those patients who started a maintenance therapy, LABA+LAMA was the most common initial therapy in both in-and outpatient diagnosed patients (33.9%/37.9%). The mean time to first severe exacerbation was 1,251 days for the older, more comorbid patients with inpatient diagnosis, and 1,403 days for outpatient diagnosed patients (p < 0.001).

This study highlights deficiencies in coding related to COPD disease severity. The reasons behind the high proportion of patients without treatment for a long period of time after inpatient diagnosis of COPD remain to be elucidated. Interdisciplinary and cross-sectoral care of COPD patients should be improved. Rationale: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019 strategy report recommends dual bronchodilator therapy is considered as initial maintenance therapy for symptomatic patients at low exacerbation risk with severe dyspnea, such as those with a COPD Assessment Test (CAT) score ≥ 20. Subgroup analyses by baseline CAT score (< 20 and ≥ 20) of the Early MAXimization of bronchodilation for improving COPD stability (EMAX) trial showed that irrespective of CAT score, greater incremental improvements in symptoms were generally observed with umeclidinium/vilanterol (UMEC/ VI) compared with UMEC and salmeterol (SAL) monotherapy. However, analyses by pre-specified subgroups may lead to an inability to detect a non-linear relationship, if one exists. This post hoc analysis assessed improvements in patient-reported symptom severity with dual-versus mono-bronchodilator therapy by baseline CAT scores using fractional polynomial modeling.

The 24-week, double-blind, parallel-group EMAX trial randomized symptomatic, inhaled corticosteroid-free patients with low exacerbation risk 1:1:1 to UMEC/VI 62.5/25 mcg once-daily, UMEC 62.5 mcg once-daily, or SAL 50 mcg twice-daily. Improvements in self-administered computerized Transition Dyspnea Index (SAC-TDI) focal score, Evaluating Respiratory Symptoms-COPD (E-RS) total score, and trough FEV1 were assessed post hoc using fractional polynomial modeling with continuous transformations of baseline CAT score covariate.

The intent-to-treat population (N=2425) included 812, 804, and 809 patients using UMEC/VI, UMEC, and SAL, respectively; mean (standard deviation) CAT score was 19.2 (6.1). Patients demonstrated greater improvements in SAC-TDI focal score at Week 24 and 4-weekly E-RS score at Weeks 21-24 with UMEC/VI versus UMEC regardless of baseline CAT score, with statistically significant benefits observed at lower CAT scores of 12-21 . Similar trends were observed for SAC-TDI and E-RS total score for UMEC/VI versus SAL, with statistically significant benefits seen across a wider range of CAT scores compared with UMEC/VI versus UMEC (data not shown). Benefit of UMEC/VI in trough FEV1 at Week 24 was also seen across CAT scores versus both UMEC and SAL (data not shown).

Conclusion: This analysis showed that irrespective of baseline CAT score, greater improvements in symptoms were observed with UMEC/VI versus either monotherapy (UMEC or SAL), suggesting that dual bronchodilator therapy may be considered for patients with COPD across a broad range of symptom severities. Fractional polynomial modeling may reveal non-linear associations and provide evidence to aid treatment decisions for individual patients.

Among those with a baseline exacerbation, exacerbation rates were significantly (p < 0.001) reduced after switching to FF/UMEC/VI; any (2.19, SD 1.52 vs 1.56, SD 1.70), moderate (1.72, SD 1.42 vs 1.21, SD 1.46), severe (0.48, SD 0.75 vs 0.36, SD 0.69). Also, among patients with a baseline severe exacerbation, rates of severe exacerbation were significantly (p < 0.001) reduced after switching to FF/UMEC/VI, from 1.30 (SD 0.68) to 0.54 (SD 0.88).

In a real-world setting, COPD patients who were treated with MITT and switched to FF/UMEC/VI had significant reductions in the rate of any COPD exacerbations. Additionally, patients who had an exacerbation prior to switching had significant reductions in the rates of any, moderate, or severe COPD exacerbation after switching to FF/UMEC/VI. Clinical Implications: Simplifying the triple therapy regimen by switching COPD patients from MITT to FF/UMEC/VI may result in better patient outcomes, as measured by exacerbations. 

Background: To this day, lung cancer still is the leading cause of cancer-related deaths. Pulmonary infections are a common complication for patients suffering from non-small cell lung cancer (NSCLC). Toxins of gram-positive and gram-negative bacteria play an important role in this, possibly by inducing radioresistance and immune escape of NSCLC cells via upregulation of PD-L1 and its interaction with its receptor PD-1.

Methods: For our in-vitro model, the human adenocarcinoma cell lines A549 and H1975 were treated with lipopolysaccharide and lipoteichoic acid prior to exposure to varying doses of ionizing radiation and direct co-culture with either Jurkat cells or human lymphocytes, both of which possess PD-1. Clonogenic survival of the NSCLC lines in co-culture with Jurkat was quantified by colony formation assay. Flow cytometry was used to measure PD-L1-expression of NSCLC cells. In addition, we quantified changes in the Jurkat cell's metabolic activity after co-culture by MTS-assay as well as the production of TNF-α and IFN-γ by lymphocytes by ELISA. Furthermore, we investigated possible reversal of the effects we discovered by immunotherapeutic targeting of PD-L1.

Results: Both stimulation with LPS and LTA significantly increased the expression of PD-L1 in A549 cells, as did ionizing radiation. In colony formation assays, performed on both A549 and H1975, LPS-and LTA-treated cells were less sensitive to radiation. The metabolic activity of Jurkat cells was significantly decreased when co-cultured with NSCLC. Similarly, TNF-α and IFN-γ levels were significantly lower when lymphocytes were co-cultured with A549.

Using a PD-L1 antibody, we were able to reverse both radioresistance of A549 and suppressed metabolic activity of Jurkat in co-culture with A549. Blocking the interaction between PD-L-1 and PD 1, however, did not have an effect on the production of TNF-α and IFN-γ by lymphocytes in co culture.

Our findings suggest that bacterial infections can contribute to induction of radioresistance in NSCLC by upregulating PD-L1. This could also possibly have an immunosuppressory effect on T-cells.

Facit: In der Differentialdiagnostik systementzündlicher Erkrankungen stellt der idiopathische multizentrische Morbus Castleman eine seltene, prognostisch bedeutsame Entität dar. Die Symptome Fieber, periphere Lymphadenopathie und Splenomegalie sollten neben dem immer hinterfragten malignen Lymphom an einen MCD denken lassen. Das Vorliegen einer Infektion durch das Humane Herpesvirus 8 und HIV sind zu prüfen. Die sichere Diagnosestellung ist ohne die histologische Referenz nicht möglich; eine zugelassene Therapie ist durch Siltuximab, einen monoklonalen Antikörper vom Typ IgG 1 Kappa gegeben, welches IL 6 inhibiert. Introduction: Patients with inflammatory rheumatic diseases (IRD) treated with the monoclonal anti-CD20 antibody rituximab (RTX) have been identified as a high-risk group for severe COVID-19 outcomes. Additionally, there is an increased risk due to a reduced humoral immune response, which is induced by the therapeutic B-cell depletion. The main intention of the study was the quantification of the humoral response after vaccination against SARS-CoV-2 in patients with IRD treated with RTX. Secondly, it was to discover which influence the time frame between the last RTX dose and the first vaccination or the status of B-cell depletion have on the antibody titer to reach a better synchronization of vaccinations against SARS-CoV-2 and the therapy regimen with RTX.

In this case-control study patients previously treated with rituximab and different IRD (mainly rheumatoid arthritis and AN-CA-associated vasculitis) were examined for their humoral immune response after completing the first series of vaccinations with the approved vaccines (BNT162b2 (Biontech/Pfizer), RNA-1273 (Moderna), (AstraZeneca/Oxford), Ad26.COV2.S (Janssen/Johnson & Johnson). The antibody levels were quantified by using the Euroimmun Anti-SARS-CoV-2 QuantiVac enzyme-linked immunosorbent assay [EI-S1-IgG-quant]. The blood samples were taken just before the next infusion with RTX after the vaccination. The interval between the last RTX infusion and the first vaccination against SARS-CoV-2 and other possible influencing factors on the antibody levels were evaluated.

Results: 102 patients were included in the study. 65 patients (64%) showed a negative antibody level ( < 24IE/ml) after the vaccination. The comparative univariate analysis of the antibody levels achieved a significant result (p=0.0008) for the time between last RTX infusion and first vaccination against SARS-CoV-2. No CD19+ peripheral B-cells could be measured in 73 of the patients (72%).

The study confirms the negative impact of the therapy with RTX on the antibody level after the vaccination against SARS-CoV-2. A clear relationship has been noticed between the antibody titer and the interval of the last infusion to the first vaccination, the number of peripheral B-cells and the quantification of immunoglobulins (IgG). These parameters could be helpful for better synchronization of vaccination and therapy regimen with rituximab.

Julius Köppen¹; Mike Recher² ¹Universitätsspital Basel, Department Biomedizin, Basel, Switzerland; ²Universitätsspital Basel, Klinik für Ambulante Innere Medizin, Basel, Switzerland Background: Kabuki syndrome (KS) is a rare congenital multisystem disorder. KS is caused by germline mutations encoding proteins for histone modification such as KMT2D or KDM6A. Abnormalities in KS include skeletal abnormalities, craniofacial defects and varying mental disability. Immunological abnormalities underlying susceptibility to infections are increasingly described in patients with KS.

We characterized a patient with KS like craniofacial dysmorphism and skeletal abnormalities. Recurrent infections suggested primary immunodeficiency (PID). Extensive immunologic phenotyping and genetic analysis using whole exome sequencing (WES) and Sanger sequencing were performed. The patient was treated with subcutaneous immunoglobulin replacement therapy which ameliorated the susceptibility to infections.

We report a 51-year-old male patient with congenital characteristic KS like skeletal morphology of the upper limbs and craniofacial abnormalities. He had repetitive bacterial airway infections requiring multiple antibiotic treatment. Immunologic phenotyping indicated a common variable immunodeficiency (CVID) defined by hypogammaglobulinemia, severe B-and T-cell lymphopenia and skewed B-and T-cell differentiation. WES demonstrated a heterozygous mutation in KMT2D (OMIM #147920) near the splicing site of exon 34/35 (c.8374C>T; p.Arg2789Trp). Sequencing of cDNA could exclude exon skipping and we did not observe a disadvantage of the mutated allele on cDNA level.

We present a novel rare KMT2D mutation associated with KS in a patient with PID. KS patients are prone to respiratory infections and repeatedly demonstrate immune deficiencies according to CVID equivalent immunophenotypes. Whether epigenetic abnormalities due to abnormal histone modifying function on KMT2D protein level cause dysregulation in B cell and T cell development should be further investigated.

Julius Köppen¹; Mike Recher² ¹Universitätsspital Basel, Department Biomedizin, Basel, Switzerland; ²Universitätsspital Basel, Klinik für Ambulante Innere Medizin, Basel, Switzerland Background: Loeys-Dietz syndrome 3 (LDS3; OMIN #613795), also known as aneurysms and osteoarthritis syndrome, is a congenital, multisystemic connective tissue disorder. Thoracic aortic aneurysms and dissections (TAAD) reflect life-threatening features. In association skeletal abnormalities and large joint arthritic degeneration characterise the clinical phenotype. LDS3 is caused by mutations in SMAD3, encoding a receptor-regulated transcription factor (R-SMAD) of the TGF-β pathway. TGF-β acts as broad mediator in tissue development and differentiation as well as in immune regulation. Immune-dysregulation in patients with LDS3 are largely under-reported.

Design: Clinical characterisation of a patient presenting with clinical features of LDS3. Immunophenotyping was performed in the context of an opportunistic atypical mycobacterial infection. Whole exome sequencing and locus specific Sanger sequencing detected a novel mutation in SMAD3. SMAD3 related gene expression in immune cells was analysed by real-time PCR.

We present a 51-year-old male patient with a novel diagnosis of LDS3. The patient received aortic root graft replacement due to annuloaortic ectasia at the age of 38 years. Skeletal abnormalities and early onset osteoarthritic degeneration strengthen diagnosis of LDS3. We describe a novel frameshift mutation in the MH2 domain of SMAD3 (c.1074delG, Ref. NM_005902.4; p. Q358QfsX8) with in-silico predicted premature protein termination. Failure of dental exfoliation -a frequent characteristic of Hyper IgE syndrome -and opportunistic infection with atypical mycobacterium kansasii prompted us to perform extensive immunophenotyping. We found immunophenotypic alterations consistent with STAT3 related hyper IgE syndrome, but CD21low B cells were almost undetectable. SMAD3 related gene expression in peripheral blood derived mononuclear cells is currently being performed.

We present a rare case of LDS3 with detection of a novel frameshift mutation in SMAD3 extending the spectrum of mutations of LDS3 with opportunistic infections. To our knowledge we describe the first extensive immunophenotypic evaluation in a patient with LDS3. LSD3 has to be considered in the differential diagnosis in patients with STAT3 dependent hyper IgE-like clinical features. S Der Internist · Suppl ·

United Kingdom; ⁷Vaccine Research, The Foundation for the Promotion of Health and Biomedical Research of the Valencia Region (FISABIO)

We assessed the disease burden of RSV in OA in community dwelling (CD-OA) and long-term care facilities

medically stable CD-OA aged ≥50 years (Europe) or LTCF-OA ≥65 yethe positive (RT-PCR) RSV-ARI episodes. Results: 45.8% of CD-OA and 32.2% of LTCF-OA had ≥1 ARI episode. RSV was detected in 4% (CD-OA) and 7% (LTCF-OA) of OA with ARI, leading to an RSV incidence proportion of 1.84% and 2.26%. In addition

Complications, mostly respiratory, were more frequent among RSV-ARI vs non-RSV-ARI episodes

LTCF) of RSV-ARI episodes. Conclusions: Despite the limited number of participants, this study showed that RSV causes disease burden in CD-OA and LTCF-OA. RSV-ARIs were more frequently associated

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Effect of Methotrexate, Anti-Tumor Necrosis Factor α, and Rituximab on the Immune Response to Influenza and Pneumococcal Vaccines in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Arthritis Care & Research

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection

Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab

The effect of disease-modifying antirheumatic drugs on vaccine immunogenicity in adults

Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies

Sterilizing immunity to influenza virus infection requires local antigen-specific T cell response in the lungs

SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area

SARS-CoV-2 vaccination in rituximab-treated patients: B cells | 358 promote humoral immune responses in the presence of T-cell-mediated immunity

The temporal course of T-and B-cell responses to vaccination with BNT162b2 and mRNA-1273

SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases

but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases. Annals of the Rheumatic Diseases

High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases

Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination

Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment

R: A language and environment for statistical computing. R Foundation for Statistical Computing

Bimba Franziska Hoyer²; Hanns-Martin Lorenz³

Tim Schmeiser⁷

Department of Rheumatology

Aber auch im Nicht-Tu-Bereich -so in der nichtoperativen Orthopädie -ließen sich subsyndromale Depressionen nachweisen

Diskussion: Aufgrund der Bedeutung von Depressionen für körperliche Erkrankungen ist ein Screening bei Tu-wie Nicht-Tu-Patienten auf depressive Symptome in jedem Falle zu empfehlen (z. B. durch Routineanwendung der im klinischen Alltag geeigneten und bewährten "Hospital and Anxiety Scale

Elevated postoperative pain levels following orthopedic surgery. Depression as a strong predictor

Preoperative depression and hospital length of stay in surgical patients

Outcomes of subsyndromal depression in older primary care patients

Excess mortality in depression: a meta-analysis of community studies

Economic costs of minor depression: a population-based study

The biology of depression in cancer and the relationship between depression and cancer Progeression

The Incidence of Mental Disorders Increases over Time in Patients with Cancer Pain: Data from a Retrospective Cohort Study

What does low psychological distress mean in patients with no mental disorders and different pains of the musculoskeletal system?

Österreichischer interprofessioneller Palliativkongress Innsbruck

PS041, PS064

PS0021, PS036, PS037, PS038, PS039, PS0044

PS074, PS075 Eisenmann, M. (Würzburg)

PS045, PS046, PS049

Köln), PS050, PS052

Mainz), PS045, PS046, PS049

Köln), PS050, PS052, PS053

PS006, PS091

PS030, PS031

München), NULL Storr, M. (Starnberg)

Stockley Park West/ Uxbridge (Middlesex))

PS045, PS046

PS049, PS055

Background: Budesonide/glycopyrronium/formoterol (BGF) triple therapy reduced exacerbation rates vs dual therapies in patients with moderate-to-very severe COPD in the ETHOS trial (NCT02465567).Aim: To assess the relationship between baseline rescue medication use and benefits of triple therapy on exacerbations in ETHOS.

Patients with a postbronchodilator FEV1 25-65% of predicted, CAT score ≥10 on ≥2 inhaled maintenance therapies, and ≥1 moderate/severe exacerbation in the prior year were randomized to BGF (320/14.4/10µg or 160/14.4/10µg) , glycopyrronium/formoterol 14.4/10µg or budesonide/formoterol 320/10µg twice-daily for 52 weeks. Treatments were administered via a single metered dose Aerosphere inhaler. Exacerbation rates were analyzed post-hoc according to baseline SABA rescue medication use (mean puffs/day: ≤4, n=5912; >4, n=2564).Results: Across treatment groups, moderate/severe exacerbations rates were higher in patients using >4 puffs/day of SABA . Benefits of BGF 320 on exacerbation rates vs dual therapies were seen in both subgroups but were greater in those with >4 puffs/day of SABA.

Triple therapy with BGF 320 reduced COPD exacerbations vs dual therapies in both subgroups, but high baseline rescue medication use may identify patients at greater risk of moderate/severe exacerbations, who may derive even greater benefit from triple therapy. 

The clinically important deterioration composite endpoint has become a recognized marker of disease stability in COPD clinical trials. This analysis investigated its corollary, the clinically important improvement (CII), which is a composite endpoint that requires concordant minimum clinically important differences (MCID) in ≥ 2 patient-reported outcomes (PROs).

The 24-week, double-blind, parallel-group Early MAXimization of bronchodilation for improving COPD stability (EMAX) trial randomized patients with symptomatic COPD and low exacerbation risk not receiving inhaled corticosteroids to umeclidinium/vilanterol (UMEC/VI) 62.5/25 mcg once daily, UMEC 62.5 mcg once daily, or salmeterol (SAL) 50 mcg twice daily. Responders to PROs were assessed a priori at Weeks 4 and 24 and were defined as: ≥ 1-point improvement in Transition Dyspnea Index (TDI) focal score, ≥ 4-point change from baseline (CFB) in St George's Respiratory Questionnaire (SGRQ) total score, ≥ 2-point CFB in COPD Assessment Test (CAT) score, and ≥2-point CFB in Evaluating Respiratory Symptoms-COPD (E-RS) total score (assessed at Weeks 1-4 and 21-24). Global Assessment of Disease Severity (GADS) was assessed at Weeks 4 and 24. Odds ratios (OR) of patients having a CII, defined as an MCID in ≥2 PROs, at Weeks 4 and 24, and ordered OR of patients with a better response category in GADS at Weeks 4 and 24 were obtained post hoc using generalized linear mixed models.

The odds of a patient achieving CII were significantly greater with UMEC/VI versus UMEC and SAL at both Weeks 4 and 24 . Among patients with 2, 3, and 4 PRO responses at Week 4 (ie, achieving CII), 67%, 87%, and 96%, respectively, had GADS improvement (ie, a better GADS response category) at Week 4, whereas among patients with 0 and 1 PRO response (ie, not achieving CII), 23% and 47%, respectively, had GADs improvement . The OR (compared with 0 positive PROs) of GADS improvement at Weeks 4 and 24 increased with the number of PRO responses at Week 4, and all ordered OR were significant versus patients with 0 PRO responses. Purpose: Previous evidence suggests significant improvement in treatment adherence in COPD patients who utilize fluticasone furoate/ umeclidinium/vilanterol (FF/UMEC/VI) compared with multiple-inhaler triple therapy (MITT). There is a lack of real-world evidence on whether improved adherence translates to improved patient outcomes. This study examined the impact of switching from MITT to FF/ UMEC/VI on moderate and severe COPD exacerbations in a real-world setting.Methods: Retrospective analysis using the Optum Research Database, which included commercial and Medicare Advantage with Part D (MAPD) enrollees age ≥ 40 years diagnosed with COPD. Included patients initiated FF/UMEC/VI between September 1, 2017 and December 31, 2018 (index date = earliest pharmacy fill for FF/UMEC/VI) and were on MITT for ≥ 30 consecutive days (overlap in the days' supply of all three triple-therapy components) during the 12 months prior to the index date. Patients with asthma, cystic fibrosis, or lung cancer were excluded. Severe (inpatient admission) and moderate (outpatient or ER visit + corticosteroid or antibiotic within ± 7 days) exacerbations were compared between the 12-month periods pre-and post-switch to FF/UMEC/VI.

In total, 912 patients were identified; mean age was 71.2 (SD 8.1) years, 51% were female, 88% had MAPD coverage, and mean baseline Charlson Comorbidity Index was 2.2 (SD 1.6). The most common comorbidities were other lower respiratory tract disease (83%), hypertension (76%), and lipid disorders (71%).Before initiation of FF/UMEC/VI, 62% of patients had a severe or moderate exacerbation vs 56% post-switch to FF/UMEC/VI (p > 0.001). The average rate of any exacerbation was significantly reduced from 1.37 (SD 1.61; MITT) to 1.20 (SD 1.54; FF/UMEC/VI; p = 0.001). The rate of moderate exacerbations was also significantly (p < 0.0001) reduced from 1.07 (SD 1.39; MITT) to 0.91 (SD 1.29; FF/UMEC/VI).

The use of PD-L1-targeting immunotherapy in combination with radiotherapy may offer therapeutic benefits. Introduction: The Standing Committee on Vaccination (Ständige Impfkommission, STIKO) in Germany recommends a standard pneumococcal vaccination for adults ≥60 years and an indicated vaccination for people with certain underlying medical conditions (including immunosuppression or some chronic diseases).

The Robert Koch Institute (RKI) regularly reports pneumococcal vaccination coverage rates (VCRs) in Germany; however, VCRs are reported either for patients with relevant underlying diseases (both at-and high-risk conditions) or for patients without any disease. Furthermore, data are not available for patients >72 years, and not regionally stratified by age.We analysed pneumococcal VCRs in 2019 in patients aged ≥60 years, regardless of their health status, and evaluated any regional differences in pneumococcal VCRs by federal state.Methods: Using the representative InGef health claims database, we retrospectively analysed a cohort among an insured population of 4.3 million in Germany. Due to data protection laws, only 6 years of observation data are available, therefore we analysed from 2014 to 2019. We used standard documentation codes for pneumococcal vaccinations, and stratified results by age group and federal state.To accurately assess the standard pneumococcal VCR in adults aged ≥60 years, we used a three-step analysis: first, we calculated the VCR of patients aged 60 to 65 years in 2019; then, we evaluated the 2019 VCR of patients aged 66 and older without a vaccination from 2014 to 2018; and finally, we determined the cumulative VCR for patients aged 66 and older in 2019.

The overall VCR for patients aged ≥60 years was 45.85%. We saw a trend towards higher VCRs with increasing age. According to age groups, those aged 60-64 had the lowest VCR (12.97%), and patients aged ≥75 had the highest VCR (69.20%), followed by those aged 70-74 (48.67%) and 65-69 (32.89%). Generally, pneumococcal vaccination rates were higher in eastern German states, compared to states in western Germany.The federal state with the lowest VCR in adults ≥60 was Bavaria (34.38%), and Saxony-Anhalt had the highest (62.63%). Similarly, stratification by federal state and age group showed the lowest VCR in Bavaria in patients aged 60-64 (7.71%), and the highest in Saxony-Anhalt (23.93%). This trend was evident in all age groups, with the highest rates in patients ≥75 (55.34% in Bavaria vs 86.11% in Saxony-Anhalt).For standard vaccination, general practitioners showed a 95% probability of administering the vaccine.

Despite STIKO pneumococcal vaccination recommendations for patients aged ≥60 years, not even half the patients in this group are vaccinated. Particularly striking is that only every eighth patient aged 60-64 is vaccinated, with huge regional differences. To adequately prevent potential illnesses, awareness both in patients and physicians must be increased. Ergebnisse: 14,4% der Probanden waren physisch inaktiv, 34,8% waren moderat aktiv und 50,8% erfüllten die Kriterien für das hohe Aktivitätslevel. Die mittlere Gesamtaktivität lag bei 3.798±3.292 MET-Min/ Woche. Die Hälfte der RA-Patienten verbrachte mehr als 45h/Woche mit sitzenden Tätigkeiten. Die stärksten Assoziationen mit Bewegungsmangel hatten Patienten mit einem körperl. Summenscore (SF-36) ≤ 28 (OR: 18, 8) , HAQ > 2,0 (OR: 16,3), DAS28 ≥ 3,2 (OR: 5,7), Rentner (OR: 5,2), Alter > 68 Jahre (OR: 3,5), CRP ≥ 5 mg/l (OR: 3,4), Röntgenstadium > III (OR: 2, 9) und Partnerlose (OR: 2,6). Probanden mit depressiver Symptomatik hatten eine signifikant geringere körperl. Gesamtaktivität als jene ohne (p=0,026), ebenso RA-Patienten mit FMS vs. ohne FMS (p=0,033). Patienten mit neuropathischen Schmerzen hatten eine signifikant höhere Sitzzeit (p < 0,001). 40% der Probanden zeigten eine pathologisch verbreiterte IMT von > 0,9 mm der re./li. ACC. Unter Berücksichtigung klassischer kardiovaskulärer Risikofaktoren erwiesen sich die Gesamtaktivität (p=0,025) und das Alter (p=0,008) als signifikante Einflussfaktoren der IMT. Der Framingham Risikoscore zeigte keinen signifikanten Zusammenhang mit der KA (p > 0,05). Die im Mittel zurückgelegte 2-Minuten-Gehstrecke lag bei 126,7±38,0 m. 88% unterschritten die für sie errechneten normativen Referenzgehstrecken. Die subjektiv gemessene KA korrelierte signifikant positiv mit der objektiv gemessenen Leistungsfähigkeit im 2MWT (r=0,433; p > 0,001).

Schlussfolgerung: Bewegung sollte eine zentrale Rolle in der Therapie der RA spielen, da diese mit besseren Outcome-Parametern assoziiert ist. Neben der klassischen Bewegungstherapie sollten auch Maßnahmen ergriffen werden, die das Bewegungsverhalten im Alltag der RA-Patienten optimieren und fördern.

Mona Arnold¹; Jana Fuchs¹; Iris Aykara²; Klaus Frommer¹; Teresa Laibe¹; Stefan Rehart³; Ulf Müller-Ladner²; Elena Neumann¹ ¹Justus-Liebig-Universiät Giessen, Campus Kerckhoff, Rheumatologie/ klinische Immunologie, Bad Nauheim, Germany; ²Kerckhoff-Klinik Bad Nauheim, Rheumatologie/klinische Immunologie, Bad Nauheim, Germany; ³AGAPLESION Markus-Krankenhaus, Orthopädie/Unfallchirurgie, Frankfurt, Germany Background: In rheumatoid arthritis (RA), osteoclasts are one of the most important mediators of bone erosion. In addition, RA synovial fibroblasts (RASF) have a major influence on joint erosion in RA. They affect osteoclast differentiation e.g. by increased RANKL production or secretion of other pro-osteoclastogenic factors such as IL-6. In addition to the pro-osteoclastogenic effect of soluble factors such as RANKL and IL-1, visfatin inhibits osteoclast differentiation. Furthermore, visfatin increases the secretion of pro-inflammatory factors by RASF, such as IL-6 or matrix degrading enzymes. In this study, the effect of RASF with/without activation by visfatin and IL-1 on osteoclastogenesis was evaluated.Methods: Blood from healthy donors and RA patients was used for PBMC isolation. RANKL, TGF-β and hM-CSF were added to induce osteoclast differentiation. RASF-conditioned media (CM) were prepared from confluent RASF cultured for 48h. Differentiating PBMCs in monoculture were compared to PBMC cultured with CM from RASF (CM: 10%, 20%, 30%) as well as in direct co-culture with RASF with/without stimulation with IL-1 (0.05ng/ml), visfatin (25ng/ml). After two weeks in culture, cells were stained using TRAP staining. 3-5 images per well were used for quantification dependent on the variability of the wells. IL-6 was measured by ELISA in supernatants collected at day 14.Results: IL-6 production increased by IL-1 (e.g. co-culture : 2,8-fold) and visfatin (CM-visfatin: 10%=4,3-fold, 20%=5,4-fold, 30%=4,2fold; co-culture: 9,5-fold) compared to unstimulated control in all settings. In addition, IL-6 was increased with the addition of CM compared to unstimulated controls (healthy donors CM 30%: unstimulated p=0.0342, IL-1 p=0.0133, visfatin p=0,0133; RA: unstimulated p=0.0133, IL-1 p=0.0342, visfatin p=0.0133, n=3 each). Of note, baseline IL-6 concentrations were higher in PBMC from RA patients compared to healthy donors. Co-culture showed an additional increase in IL-6 levels in all settings (e.g. monoculture: IL-1 4.71±5.75pg/ml, visfatin 141.09±182.79pg/ml; co-culture: IL-1 7241±10398pg/ml, visfatin 24535±16994pg/ml;). During osteoclast differentiation, addition of CM showed similar osteoclastogenesis with similar proportion of osteoclasts with 2 and 3-5 vs. higher numbers of nuclei per cell compared to control. In coculture with RASF osteoclasts showed a stronger TRAP signal compared to monoculture especially for unstimulated and IL-1 stimulated co-cultures.

Both, in monoculture with CM and in coculture, IL-6 levels were increased compared to control, whereas in RA patients the IL-6 levels were higher compared to healthy donors. The CM containing secreted factors of RASF did not have a prominent influence on osteoclastogenesis. However, the presence of RASF increased the TRAP signal showing an increased activity of differentiated osteoclasts especially in unstimulated and IL-1 stimulated co-cultures but not with addition of visfatin.

Introduction: At the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 pandemic the influence of anti-inflammatory therapy on the course of COVID-19 was unknown. In the meantime, several data indicate an association of severe COVID-19 with the use of rituximab (RTX) in patients with inflammatory rheumatic diseases (IRD). RTX, an anti-CD20 chimeric monoclonal antibody that depletes CD20-expressing B cells is used in a broad range of conditions, including IRD and lymphoma. To gather further knowledge about SARS-CoV-2 infections in RTX-treated IRD patients, data from the German COVID-19-IRD-registry were analysed.Methods: Data from the German COVID-19-IRD registry, collected by treating rheumatologists between March 2020 and December 2021 were analysed. Hospitalisation was used as asurrogate of COVID-19 severity. Baseline characteristics, disease features, medication and outcome of COVID-19 were compared in both groups.

In total, 3592 cases were reported in the registry, which included 130 RTX patients (3.6%) for our analysis. RTX-treated inpatients were older than RTX-treated outpatiens (median age 63 y vs 56 y, p=0.007). Patients with granulomatosis with polyangiitis treated with RTX (n=32) showed a significant higher hospitalization rate (33% vs 11%, p=0.005), which was not the case for patients with rheumatoid arthritis (49% vs 50%). Cardiovascular comorbidities were reported more frequently in hospitalised RTX-treated patients (20% vs. 6%, p=0.032). More than 50% of the RTX-treated inpatients developed CO-VID-19 related complications, e.g. acute respiratory distress syndrome. The time period between the last RTX treatment and SARS-CoV-2 infection was shorter in inpatients than in non-hospitalised patients (3 (range 0-17) vs. 4 months (range -29), p=0.039). The COVID-19 related mortality rate was 14% (n=19) in RTX-treated IRD patients. In both groups, there were no relevant differences with respect to the use of concomitant glucocorticoids, disease activity, RTX dose or number of immunomodulatory drugs prior to RTX treatment.

In addition to general risk factors, such as age and comorbidities, it is already known that IRD patients treated with RTX show a higher rate of severe COVID-19. In our registry, RTX-treated patients with granulomatosis with polyangiitis appear to be at even higher risk to develop severe COVID-19 compared to other IRD. Mo-reover, the shorter the time elapsed since RTX treatment, the higher seems to be the risk of developing severe COVID-19. This might be explained by a more profound B-cell depletion in the first weeks after RTX treatment. Patienten und Methoden: Überblick über den Erkenntnisstand der bisherigen Studienaktivität zum Forschungsgegenstand, der Korrelation von Depression und benignen bzw. malignen Erkrankungen, im Fallaufkommen am Universitätsklinikum Magdeburg A.ö.R. (tertiäres Zentrum mit hochspezialisierter Betreuung) -zum einen im Rahmen einer klinisch-systematischen prospektiven unizentrischen Beobachtungsstudie (Design) eines interdisziplinär-klinischen Forschungsteams (Schmerztherapie und Bereich Allgemein-/Viszeralchirurgie der berichtenden Kliniken) an einer konsekutiven Patientenkohorte mit repräsentativer Fallzahl über einen definierten Untersuchungszeitraum zur Reflexion der klinischen Alltagsrealität ("real-world data") und darüber hinaus weitere themenbezogene Untersuchungen.

Die Patienten-, Symptom-, (Depressions-/Tu-)Befund/-Diagnose-und Outcome-assoziierten Daten wurden in Excel-basierten Computerdateien erfasst und einer deskriptiv-sowie testend-statistischen Auswertung unterzogen, Ergebnisse (selektive Eckpunkte) -Der Schweregrad der F3-Depressionen nahm im Laufe der Zeit ab. In den letzten Jahren stieg der Anteil psychisch unauffälliger Nicht-Tu-Patienten von 33,3 auf 47,5 %.-Bei Tu-Patienten war zumindest für einzelne Tu-Arten dagegen mit den Jahren des Überlebens eine Zunahme psychischer Diagnosen zu verzeichnen. So stieg bei Tu des Urogenitaltrakts der Anteil psychischer Diagnosen von Akutpatienten von 37,2 auf 74,1 % bei Langzeitüberlebenden.-Bei den Nicht-Tu-Patienten war trotz abnehmender Zahl psychischer Störungen der Anteil von F3-Diagnosen annähernd konstant (lediglich moderat steigender Trend von 15,5 auf 17,1 %) -bei den Tu-Patienten dagegen stieg er von 2,3 auf 14,8 %.-Gerade bei Tu-Patienten ließen sich depressive Symptome auch im subsyndromalen Bereich darstellen. So war zu eruieren, dass psy-